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ABSTRACT 
We propose a novel solution to prevent cancer by developing a 
prophylactic cancer. Several sources of antigens for cancer vaccines have been 
published.  Among these, antigens that contain a frame-shift (FS) peptide or viral 
peptide are quite attractive for a variety of reasons. FS sequences, from either 
mistake in RNA processing or in genomic DNA, may lead to generation of neo-
peptides that are foreign to the immune system.  Viral peptides presumably would 
originate from exogenous but integrated viral nucleic acid sequences. Both are 
non-self, therefore lessen concerns about development of autoimmunity. I have 
developed a bioinformatical approach to identify these aberrant transcripts in the 
cancer transcriptome. Their suitability for use in a vaccine is evaluated by 
establishing their frequencies and predicting possible epitopes along with their 
population coverage according to the prevalence of major histocompatibility 
complex (MHC) types. 
Viral transcripts and transcripts with FS mutations from gene fusion, 
insertion/deletion at coding microsatellite DNA, and alternative splicing were 
identified in NCBI Expressed Sequence Tag (EST) database. 48 FS chimeric 
transcripts were validated in 50 breast cell lines and 68 primary breast tumor 
samples with their frequencies from 4% to 98% by RT-PCR and sequencing 
confirmation. These 48 FS peptides, if translated and presented, could be used to 
protect more than 90% of the population in Northern America based on the 
prediction of epitopes derived from them. Furthermore, we synthesized 150 
peptides that correspond to FS and viral peptides that we predicted would exist in 
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tumor patients and we tested over 200 different cancer patient sera.  We found a 
number of serological reactive peptide sequences in cancer patients that had little 
to no reactivity in healthy controls; strong support for the strength of our 
bioinformatic approach. 
This study describes a process used to identify aberrant transcripts that 
lead to a new source of antigens that can be tested and used in a prophylactic 
cancer vaccine. The vast amount of transcriptome data of various cancers from 
the Cancer Genome Atlas (TCGA) project will enhance our ability to further 
select better cancer antigen candidates. 
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CHAPTER 1  
INTRODUCTION 
 Cancer is one of the leading causes of death in the United States and many 
other countries. Currently, one in four people will die of cancer in the United 
States. In total, 1,596,670 new incidents and 571,950 deaths from cancer are 
projected to occur in the United States in 2011. The chance of being diagnosed 
with an malignant cancer in a lifetime is 44% and 38% for men and women 
respectively (1). Cancer is a major threat to public health and is in desperate need 
for a cure. 
1.1 Why a ‘Prophylactic’ Cancer Vaccine? 
 One common treatment for cancer is surgery, whose effectiveness is 
related to how early the cancer is detected. Chemo-therapy may be associated 
with considerable amount of side-effects. One potential approach is to cure cancer 
by the development of cancer vaccines. Vaccination is one of the most effective 
ways to treat infectious diseases in the history of medicine as 26 infectious 
diseases are preventable through vaccination (2). Vaccination against cancer has 
multiple advantages over existing treatments, including tumor specificity through 
personalization, minimal toxicity, and long-term therapeutic effect due to 
immunological memory (3). Data has been accumulated from human and mouse 
studies that provide strong evidence that the immune system is involved in tumor 
rejection (4-10). This suggests a possibility that the immune system could be 
trained against the tumor. 
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 Over the past two decades, there have been considerable efforts to turn the 
patient’s immune system against pre-existing tumor. These attempts encompass 
the use of whole cells, peptides, genetically modified tumor cells, heat-shock 
proteins, or apoptotic tumor cells to elicit the host’s immune response to cancer 
cells (11, 12). However, therapeutic cancer vaccination has not proved strong 
enough to eradicate malignancies consisting millions of tumor cells. Total tumor 
burden, immune suppression induced by tumors, immune escaping are all hurdles 
for a therapeutic vaccines to work (2). Therapeutic tumor vaccines have been 
extensively examined in animal models and in clinical trials. However, these 
approaches have not been successful in clinical settings (13). One of the main 
problems in a therapeutic approach to cancer vaccines include lack of high 
affinity response, autoimmunity, otherwise, immune tolerance (and even immune 
escape) of tumor by cancer immunoediting (14), which is largely due to priming 
the self-antigens. 
  In the case of prophylactic vaccine, we can avoid the insurmountable 
obstacles that affect therapeutic cancer vaccines. An enhanced immune system, 
exposed to a tumor antigen by vaccination, is expected to kill the tumor before it 
reaches a stage of cancer in which it will suppress and evade the immune system. 
The cancer vaccines are most effective in protection from tumor challenge based 
on animal studies (15). Autoimmunity will be a significant concern. Indeed, it 
makes the development of a cancer vaccine more difficult that tumors largely 
express ‘self’ antigens. Nevertheless, several tumor antigens have been identified 
and cancer vaccines against these antigens have been reported in pre-clinical 
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studies to induce tumor-specific immune responses and result in long-term 
memory without autoimmunity (7, 16-20).  
 Non-self antigens have been shown to generate high-avidity T cell 
responses more readily than self antigens (21, 22). The discovery of tumor-
specific neo-antigens is crucial for vaccine development in order to develop 
effective cancer vaccines. The success of vaccine against infectious diseases also 
indeed comes from the fact that the causative agents of most infectious diseases 
have been already reported and isolated. Tumor-specific antigens decrease the 
risk of autoimmunity and at least systemic tolerance, which is especially critical 
in prophylactic vaccines. Tumor-specific neo-antigens in tumors enable us to 
develop effective prophylactic cancer vaccines as well as possible therapeutic 
ones. 
1.2 What is the optimal tumor antigen? 
 Selecting and determining the appropriate antigens that elicit a specific 
antitumor immune response is one of critical challenges of developing a cancer 
vaccine. What are tumor antigens? And what makes antigens ideal for vaccine? 
“Virtually any mutant, over-expressed or abnormally expressed protein in cancer 
cells, can serve as a target for cancer vaccines and/or T-cell therapy” (23). 
Basically, any protein that can distinguish tumors from normal have the potential 
to be tumor antigens. Functionally, tumor antigens may be classified as self or 
non-self (neo-antigens) (11). Self tumor antigens are derived from non-mutated 
genes that meet one of following conditions (23); i) expressed limited to only 
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fetus (oncofetal) or dispensable normal tissues such as prostate or ovary 
(differentiation), ii) expressed higher in cancer (over-expression), and iii) 
expressed in cancer with unique post-translational modification. Non-self antigens 
are derived either exogenously or endogenously. Peptides from cancer associated 
viruses can be exogenous non-self antigens. Endogenous non-self antigens are 
generated from mutated proteins that arise as a consequence of genetic alterations 
in tumors. A diagram is show in Figure 1.1. The analysis of Cheever et al. 
provided the list of 75 representative cancer antigens under investigation. They 
also suggested nine criteria to evaluate whether they are appropriate antigens; i) 
therapeutic function, ii) immunogenicity, iii) oncogenecity, iv) specificity, v) 
expression level and % positive cells, vi) stem cell expression, vii) number of 
patients with antigens-positive cancers, viii) number of epitopes and ix) cellular 
location of expression. 
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Figure 1.1 Types of tumor antigens There are two types of antigens by their 
origin. Non-mutated gene can generate self antigens when they are deregulated in 
cancer. Mutations or infections can generate neo-antigens. 
1.3 Why neo-antigens? 
 Self antigens have two main limitations: autoimmunity and immune 
tolerance. Use of self antigens in a vaccine may lead to autoimmune toxicities 
(24). The risk of autoimmune reactions after vaccination has been observed in 
animal models (25-27), as well as in clinical trials where melanoma patients who 
have developed vitiligo (loss of pigmentation due to destruction of melanocytes) 
(28, 29). In addition, self-antigens run the risk of being non-immunogenic thus 
incapable of breaking immune tolerance (30, 31). “Unlike self-antigens, neo-
antigens (non-self antigens) can avoid the risk of autoimmunity and at least 
systemic tolerance”(23). Therefore, tumor antigens uniquely represented in 
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the tumor and not in normal tissues may be better candidates for a 
prophylactic vaccine in general. 
 According to Cheever et al. (23), the majority of the examined antigens 
are self-antigens while only 11 are non-self antigens (Figure 1.2). In fact, none of 
them are derived from frame-shifted mutations. The potential of neo-antigens as 
cancer vaccine antigens, especially frame-shifted, has not been examined 
intensively. The suggested list of neo-antigen candidates provided by this study 
would be a good start for testing the potential of neo-antigens as cancer vaccine 
antigens. 
 
Figure 1.2 Classification of 75 antigens from Cheever et al. This diagram 
shows the uneven distribution between self and non-self antigens under current 
investigation. 
1.4 Source of neo-antigens 
 Neo-antigens can originate either exogenously (such as viral proteins from 
HPV16) or endogenously. The latter ones include un-mutated proteins that have 
never been exposed to an immune system (such as embryonic antigens) as well as 
mutated proteins created by genetic changes in tumors (11). The major types of 
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genetic changes in tumors are: subtle sequence changes in nucleic acids, 
alterations in chromosome number, rearrangements of chromosome, and gene 
amplifications/deletions (32). Among these changes, we consider the framesift 
(FS) as a powerful source of tumor-specific antigens because unique sequences 
from FS are more likely than point mutations to contain longer sequences and 
parts of these neo-sequences will be presented on the surface of cancer cells in the 
context of MHC class I molecules (33). We propose that neo-antigens derived 
either from viruses (exogenous) or frame-shifted mutations (endogenous) are 
ideal antigen candidates. The immune system should react more strongly against 
tumors presenting peptides from a viral origin rather than to tumors presenting 
endogenous non-mutated peptides, which have been exposed to negative 
selection. Since most cancers are the result of accumulated genetic alterations 
rather than viral infections, endogenous antigens may still be the predominant 
tumor targets. Some of these antigens will be neo-antigens arising from 
mutations. Specifically, alteration of the reading frame caused by genetic changes, 
frame-shift mutations, may generate ‘immunogenic’ C-terminally truncated 
proteins with a neo-peptide tail that stretches beyond the mutation until a stop 
codon is encountered. The use of FS peptides as tumor antigens was first 
suggested by Townsend et al in 1994 (33). Since then, several studies have shown 
the potential of FS peptides as novel antigens for cancer treatments by inducing 
tumor-specific cell-mediated immunity (34-39). There are three types of 
mutations that induce frame-shifted peptides: chimeric transcripts, 
insertion/deletions, splicing variants. First, the chimeric transcripts are potential 
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source of immunogenic tumor-specific antigens derived from new antigenic 
peptides at a junction or breakpoint: new combination of two peptides or induced 
frame-shifted peptides. Imatinib targets the bcr-abl fusion gene. It has shown a 
remarkable success in cancer treatment. Furthermore, several studies have shown 
that fusion peptides can elicit HLA-restricted CTL reactions to lyse tumor cells 
(40-42). Second, the coding microsatellites (MS) DNAs in genes can also 
contribute immunogenic tumor-specific antigens by FS mutation due to their 
propensity for insertion-deletion (Indels) mutations with high mutation rate (43-
45). Several initial studies have shown the frequent insertion/deletion at the 
coding MS DNA of TGFβ-RII, BAX, hMSH3, hMSH6, and IGFIIR genes in the 
microsatellite instability (MSI) colorectal cancer (15% of colorectal carcinoma) or 
hereditary nonpolyposis colon cancer (HNPCC). According to Duval and 
Hamelin  (46), the mutations frequency of coding MS DNA for MSI colorectal 
cancer and HNPCC were 81% and 76% respectively for TGFβ-RII, 45% and 49% 
for BAX, 38% and 51% for hMSH3, 22% and 24% for hMSH6, and 17% and 7% 
for IGFIIR. Currently, about 400 genes with coding repeats were surveyed in the 
database called “SelTarbase” (47). Besides, there are more than 7,000 unexplored 
MS DNAs from in the coding sequences of 4,000 genes. Third, alternative 
splicing variants are also good source of generating FS peptides by skipping 
exons of which the length is not divisible by three. Recent studies showed that 
alternative spicing is much more frequent than expected. According to Wang et 
al., 92-94% of human genes have splicing variants, which has been proposal as a 
major contributor to human phenotype variability given our relative small genome 
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(48). Furthermore, several studies showed that some splicing event significantly 
differed in tumors relative to corresponding normal tissues (49, 50). 
1.5 Strategies for identifying neo-antigens 
 The identification of neo-antigens is not an easy task in most cases of 
sporadic tumors raised from spontaneous genetic alterations since tumor cells are 
transformed from normal cells. Neo-antigens can be identified by screening 
immune response of cancer patients. This approach would be lengthy and 
expensive. We are able to obtain putative neo-antigens by analyzing the 
transcriptome or proteome in cancer and normal samples. Neo-antigens from this 
approach have to be confirmed by experimental validation.  The advent of high-
throughput sequencing technology provides access to massive transcriptome data 
from various sources. However, high-throughput proteome analysis has not yet 
been well established. Therefore, we started to analyze caner and normal 
transcriptomes to identify putative neo-antigens. Analysis of the EST database 
(51) provides us with the opportunity to define novel tumor-specific changes and 
their patterns. Several studies have demonstrated that EST analysis facilitated the 
identification of relevant mutations in tumors, including chimeric transcripts, and 
mutation pattern (52-57). The same principle can be applied to the recent RNA-
seq data (58-62) from tumor and normal tissues. I proposed a study illustrated in 
Figure 1.3. 
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Figure 1.3 Goal of study. We set the pipeline of transcriptome analysis for identifying 
putative neo-antigens on the behalf of cancer vaccine development. Red bar indicates a 
frame-shift mutation while dotted line indicates a viral sequence. 
 
 In summary, identified frame-shifted and viral peptides from the 
transcriptome analysis are promising as antigens for inclusion in cancer vaccines, 
but little is known about their frequency let alone their efficacy for the cancer 
vaccine. The systemic screening of these alterations in all different types of 
tumors is required to establish their frequency (in one type of tumor) and 
prevalence (among different types of tumors). This information is crucial in 
accessing the feasibility and direction of cancer vaccine development as well as in 
choosing the right antigens. To address this important question, we propose i) to 
develop a methodological strategy for establish the frequency and prevalence of 
mutations in human cancers and ii) to identify potential effective tumor-specific 
antigens for a cancer vaccine. The analyses described in this document such as 
their frequency, tumor-specificity, and population coverage according epitope 
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prediction enable us to suggest novel effective neo-antigens for cancer vaccine 
development. According to the findings from this study, we will be able to impact 
the direction of cancer vaccine development. Also, the list of tumor-specific 
genetic alterations derived from this study will give us better a understanding of 
tumor biology as well as many other applications such as cancer biomarker, 
diagnosis, prognosis, microarray probes and so on. 
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CHAPTER 2  
VIRAL SEQUENCES 
2.1 Introduction 
 Viruses associated with the development of cancer could be the most 
obvious and useful tumor-specific markers as they do not originate endogenously. 
The idea that viruses could be associated with cancer has been around for nearly 
100 years, since 1911 when Peyton Rous isolated an avian virus from chicken 
sarcoma (63, 64). Several infectious agents, especially viruses, are considered to 
be oncogenic in humans as shown by Javier and Butel and Martin and Gutkind 
(63, 65). This known list includes human papilloma virus (HPV), hepatitis B virus 
(HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), Human T-
lymphotropic virus (HTLV-1), and Kaposi's sarcoma-associated herpesvirus 
(KSHV). In addition, several studies suggested that Merkel cell polyomavirus, 
human immunodeficiency virus (HIV), Molluscum contagiosum virus (MCV) and 
simian 40 (SV40) may have a potential link to development of human cancers. 
According to Parkin’s study, about 17.8% of global cancer incidents associated 
with infection in 2002 (66) and the presence of HPV type 18 has been reported to 
be as high as 20% in cervical cancer (67).  
 The identification of cancer-associated viruses has two important 
implications. First, tumor-associated viruses advance our understanding of tumor 
instigation and development (68). The discovery of oncogenes and tumor 
suppressors was derived from the study of RNA tumor viruses and DNA tumor 
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viruses respectively. The function of the src gene was discovered and recognized 
as an oncogene during debates on their cellular or viral origin. The famous tumor 
suppressor gene, p53, was discovered during the study of SV40 large T antigens. 
Many other molecular mechanisms of cancer were revealed from research of 
cancer-associated viruses. Second, identification of tumor-associated viruses 
enabled us to develop vaccines against them which in turn lowers the risk for 
cancer (69). The HPV and hepatitis vaccines are expected to lower the risk for 
cervical cancer and hepatocellular carcinoma respectively. Chang reported that 
the incidents of hepatocellular carcinomas (HCC) dropped from 10-17% to 0.7-
1.7% after the HBV vaccination program started in Taiwan twenty years ago (70). 
 Hausen, who discovered the role of papilloma virus in cervical cancer, 
promoted the search for additional viruses with a link to malignancy. In toto, the 
list of cancer-associated viruses is quite short compared to their contribution to 
cancer worldwide. However, the discovery of new causative viruses with diseases 
including cancers has been a very arduous task (71). The availability of sequences 
from tumors provides us the opportunity to detect the viral sequences in human 
cDNA libraries from various sources. Several studies have detected viral 
sequences in the human transcriptome (72-75). The purpose of our study is to 
identify viral sequences in existing database in order to provide a list of putative 
cancer-associated viruses. We have taken a bioinformatic approach to determine 
the presence of viral sequences in expressed sequence tag (EST) databases from 
NCBI. We show that some viruses sequences were more prevalent in tumors than 
normal tissues. Furthermore, we examined the abundance of open reading frames 
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(ORFs) of viruses in order to show differential expression among viral peptides. 
This study showed that viral sequences can be reliably detected amidst the 
abundance of human transcriptome sequences. The suggested list of virus 
candidates provided by this study would be a good start for an immunological 
study.  
2.2 Bioinformatic analysis 
2.2.1 Data Sets  
Five different data sets were obtained from the National Center for 
Biotechnology Information (NCBI); Expressed Sequence Tag (EST) (51), human 
reference sequences (RefSeqs), set of complete viral genomes, Univec database, 
non-redundant (nr) nucleotide database.  About 8.3 M sequences from 49 
different tissues types of tumor and normal had been deposited into EST database 
of NCBI. 4,004,495 sequences in 2,729 libraries were obtained from normal 
samples while 3,252,458 sequences in 4,992 libraries were obtained from tumor 
samples. 3,873 complete viral genome sequences were retrieved from NCBI by 
querying “viruses [Organism] AND reference sequences”. Human mammary 
tumor virus (AF243039) was not identified by this query, I manually added it. For 
identification of ESTs derived from human transcripts, I made use of human 
Reference Sequences (RefSeq) for identifying human transcripts (76). To 
eliminate vector sequences in EST database, UniVec database was employed 
(ftp://ftp.ncbi.nih.gov/pub/UniVec/). UniVec database contains vector sequences 
as well as sequences of adapters, linkers, and primers for cloning. Last, I used 
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non-redundant nucleotide database other than human and viruses in order to 
ensure that possible alignments from other organisms were removed 
(ftp://ftp.ncbi.nih.gov/blast/db/FASTA/). 
2.2.2 Identification of EST sequences derived from viruses  
 Basically, I used stand-alone BLAST program to identify putative viral 
sequences in the EST sequences. The EST sequences that aligned with human 
RefSeq was filtered out. Good alignment implied that length of alignment was 
≥100 bp with minimally 85 % sequence similarity or aligned length ranged 
between 50 to 100bp with ≥90% sequence similarity. Not all EST sequences 
aligned with human RefSeq using the above filter; these were considered as not 
originated from human transcripts. These were considered as contaminants or 
exogenous origin. We used them for further analysis: I aligned these excluded 
EST sequences with the complete viral genomes. To ensure we captured short 
alignments, we adjusted our criteria to >50 bp, >90% similarity or >35 bp, >97% 
similarity. Sequences that matched viral sequences were further filtered by 
content from the UniVec database (vector sequences). BLAST scores of viral was 
compared to vector sequences. Those viral ESTs that scored at least 50 or more 
over vector sequences were kept. To further reduce false positives, we aligned the 
remaining EST sequences against non-redundant nucleotide sequences excluding 
viral and human sequences. BLAST scores against viral sequences had to be at 
least 50 or greater than scores from non-redundant nucleotide sequences. Finally, 
those ESTs that remained after two filtering steps were presumably of viral origin. 
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2.2.3 Frequency analysis of virus and their open reading frame (ORF)  
 Using putative viral EST sequences, we estimated the frequency of their 
incident in tumor and normal samples. Some sequences   traced back to a single 
viral sequence while others were not resolved clearly due to shared sequence 
similarity across multiple viral sequences. When scores from the best alignment 
were higher than scores from any other by at least 50 or more, this EST sequence 
was considered as a single origin. I used mainly viral EST sequences with unique 
origin to count the frequencies of corresponding viruses. The same principle was 
applied to counting the prevalence of ORFs except for highly repetitive viral 
sequences. In this case, we counted them multiple times for every supporting 
ORFs.  
2.3 Results 
2.3.1 Identification of viral EST sequences in EST Db  
 BLAST program was used to identify putative viral sequences from 
expressed sequences tag (EST) databases. We identified EST sequences that 
conservatively would not align with any human reference sequences (RefSeq) or 
vector sequences (Figure 2.1).  
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Figure 2.1 The scheme of identification of viral EST sequences. All EST 
sequences were aligned with human reference RNA sequences (RefSeq) by using 
BLAST program. The EST sequences that did not aligned with any RefSeq were 
then aligned with complete viral genomes. 
 First, all EST sequences (approximately 8.3 M) were aligned to human 
RefSeq. 16% (1,298,128 sequences) would not align with any RefSeq at all 
according to our criteria (see Methods). These ‘no hit’ EST sequences were 
aligned with known viral sequences from NCBI. There were 11,221 ESTs that 
aligned with viral sequences according to our criteria (see Methods). These 
sequences were subject to BLAST analysis against the UniVec database in order 
to remove vector sequences. 10,440 ESTs were removed. The remaining 781 EST 
sequences were compared to the non-redundant nucleotide database excluding 
human and viruses in order to determine whether these sequences originated from 
sources other than viruses. 26 EST sequences originated from mouse or other 
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non-viral sources. We obtained 755 putative viral EST sequences.  Another set of 
viral ESTs were detected from removed human sequences that had coincidental 
viral homology. We blasted these sequences against viral sequences. If this blast 
score was at least 50 more than human, we regarded these ESTs as viral 
originated. 8 ESTs were obtained from this process. A total of 763 putative viral 
ESTs were selected for further analysis.  
2.3.2 Identification of putative tumor-associated viruses  
 Based on the alignments of EST sequences with viral genomes, there are 
two types of viral EST sequences identified (see Methods). 572 viral EST 
sequences were evidently traced back to one virus while 183 sequences were not 
resolved as to their origin as clearly. 22 viruses were supported by 572 viral EST 
sequences. 15 out 22 viruses were found in at least one tumor library by using 
viral EST sequences of unique origin (Table 2.1). 6 viruses (squirrel monkey 
retrovirus, Human papillomavirus type 16, Choristoneura occidentalis 
granulovirus, Moloney murine leukemia virus, Parainfluenza virus 5, and Mouse 
mammary tumor virus) were detected only in tumor libraries. Some viruses such 
as Human papillomavirus 18, Murine type C retrovirus, Enterobacteria phage 
phiX174 sensu lato were present more in tumor than in normal libraries. 
Furthermore, we checked seven known cancer-associated viruses and four 
suspected viruses as proof of concept (Table 2.2). Five were detected by our 
approach while three (hepatitis C virus, Human T-lymphotropic virus1, and 
Simian virus 40) were filtered out by one of our criteria. If our filter steps were 
too strict, we may miss portions of viral sequences. So, I performed the entire 
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analysis without filtering. Given the higher possibility of false-positives, 
supplementary Table 1 contains this list of viruses. Beside the 22 viruses, 50 
additional were found if the lower stringency filtering is used (supplementary 
Table A.1).  
Table 2.1 The list of putative cancer-associated viruses. From our analysis of 
EST sequences, 20 viruses were supported by at least one EST sequence from 
tumor libraries. 6 viruses were found only in tumors. 4 viruses were dominantly 
found in tumor over normal samples. ‘?’ indicated uncharacterized tissue type. 
Numbers in ( ) showed the number of EST sequences in each library. For 
instance, Uterus (1,3,2,1) means that four libraries from uterus and each library 
has 1,3,2 and 1 supporting viral ESTs respectively. 
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Table 2.2 The list of known cancer-associated viruses This table contains the 
results for viruses either know to cause or suspect to contribute to human cancers. 
Five of them were detected in our approach while three viruses were retrieved 
only after removing some of our filters (see Methods). Three viruses were not 
present in the whole EST sequences. Overall, 8 out of 11 known cancer associated 
viruses were detected in EST sequences even though some of them were also 
found in libraries from normal. 
 
2.3.3 Prevalence of open reading frame (ORF)  
 There were three viruses with more than 10 supporting viral EST 
sequences - Human papilloma virus 18 (HPV18), Hepatitis B virus (HBV), and 
Simian virus 40 (SV40). We enumerate the EST sequences that corresponded to 
each ORF on a per virus basis. Even distribution was not observed across multiple 
ORFs in a virus (Figure 2). Among 8 ORFs of HPV18, 5 ORFs had supporting 
viral EST sequences and most of them originated from only three ORFs; E6, E7, 
and E1 protein. Viral EST sequences from HBV derived from 3 out 7 ORFs. Most 
belonged to either X protein or Polymerase. In the case of SV40, viral EST 
sequences were found in libraries more from normal than from tumor in overall. 
However, 3 ORFs had more tumor libraries than normal ones among 5 ORF 
presented in EST sequence database.   
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Figure 2.2 The prevalence of open reading frame (ORF) in a virus. The 
uneven distribution of supporting viral EST sequences among ORFs was observed 
for most of viruses. For the case of HPV18, 5 out of 8 ORFs had supporting viral 
ESTs and many of them originated from E6, E7, and E1. In fact, E6 and E7 are 
known as oncogenic proteins. Among 10 ORFs from Hepatitis virus B, 6 ORFs 
yielded viral ESTs. 6 viral EST sequences from tumor originated from 6 ORFs 
while 45 viral EST sequences from normal originated from only 3 ORFs. Viral 
EST sequences of simian virus 40 were found more in normal than tumor. 
However, 3 ORFs had more viral ESTs from tumor and normal. 
2.3.4 Immune response against viral peptides  
 We selected and synthesized 48 predicted B cell epitopes (see 
supplementary Table A.2) from 30 putative tumor-associated viruses (Table 2.3).  
Some of peptides were shared by multiple viruses. For instance, APDNDDPNFE 
is found in Rachiplusia ou MNPV, Plutella xylostella multiple 
nucleopolyhedrovirus, Bombyx mori NPV, Bombyx mandarina 
nucleopolyhedrovirus, and Autographa californica nucleopolyhedrovirus. 
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Table 2.3 The list of viral epitopes on the cancer chip. 48 peptides on peptide 
array were the putative B cell epitopes derived from 33 distinctive viruses. ‘# of 
epitopes’ indicates how many epitopes from a virus and ‘Viral proteins’ indicates 
their specific origins. 
 
 
 We used a peptide chip with the 48 spotted peptides to analyze the sera 
from 443 human samples; 162 normal samples, 102 breast cancer samples, 84 
lung cancer samples, and 95 pancreatic cancer samples. After normalization of all 
intensity in the data to median of 1.0, we set the bar at 7.0 or higher for defining 
high reactivity. Two peptides showed high reactivity frequently in breast tumor 
samples relative to normal samples. PYDPEDPGQE was detected in 7 distinctive 
viruses including Xenotropic MuLV-related virus while PRRRTPSPRRRRSQ 
Virus # epitopes Viral protein
Human herpesvirus 4 type 2 3  BPLF1 , BALF3 , EBNA-3C 
Friend murine leukemia virus 1  gag protein 
Human papillomavirus type 16 1  E1 
Bovine viral diarrhea virus 1 1  polyprotein 
Canine parvovirus 1  polyprotein 
Rachiplusia ou MNPV 2  DNA helicase , global transactivator 
Parainfluenza virus 5 3  V protein , phosphoprotein , hemagglutinin-neuraminidase protein 
Human papillomavirus - 18 2  L1 protein , E1 protein 
Squirrel monkey retrovirus 2  protease , gag protein 
Plutella xylostella multiple nucleopolyhedrovirus 2  DNA helicase , global transactivator 
Pestivirus Giraffe-1 1  polyprotein 
Simian virus 40 2  large T antigen , Major capsid protein VP1 
Xenotropic MuLV-related virus VP62 2  putative gag-pro-pol polyprotein , putative gag polyprotein 
Enterobacteria phage ID18 sensu lato 2  gpB , gpH 
Bombyx mori NPV 2  DNA Helicase , GTA 
Woolly monkey sarcoma virus 4  Env protein , pre-gag ORF protein , p28sis , hypothetical Gag polyprotein 
Beilong virus 2  W protein , nucleocapsid protein 
Hepatitis B virus 4  Core and e antigen , precore/core protein , middle S protein , large S protein 
Human herpesvirus 4 3  BZLF1 , BPLF1 , BALF3 
Moloney murine leukemia virus 2  Pr65 , Pr180 
Murine type C retrovirus 1  hypothetical protein MtCrVgp1 
Human herpesvirus 5 2  DNA polymerase catalytic subunit , membrane glycoprotein UL18 
Bombyx mandarina nucleopolyhedrovirus 2  DNA helicase , GTA 
Human adenovirus C 2  single-stranded DNA-binding protein , control protein E4orf6/7 
Autographa californica nucleopolyhedrovirus 2  global transactivator-like protein , helicase 
Abelson murine leukemia virus 1  p120 Gag-Abl polyprotein 
Human herpesvirus 8 2  vIRF-3 , KCP 
Rauscher murine leukemia virus 1  gag polyprotein 
Moloney murine sarcoma virus 1  Pr65 
Spleen focus-forming virus 1  gag polyprotein fragment 
Human herpesvirus 1 2  thymidine kinase , DNA replication origin-binding helicase 
Murine osteosarcoma virus 1  gag polyprotein 
Human immunodeficiency virus 1 2  Vpr , Nef 
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was found only in Hepatitis B virus. Other two peptides showed high reactivity 
frequently in pancreatic tumor samples relative to normal samples. One of them, 
TGAESEDSGDEGPSTRH from Kaposi Sarcoma virus, showed also high 
reactivity frequently in colon tumor samples relative to normal samples (Figure 
2.3). Several viral epitopes were highly reactive in many samples from every 
group including normal samples while 23 viral epitopes did not show any 
reactivity in any samples. 
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Figure 2.3 High reactive four viral epitopes in cancer samples. Two peptides 
(A, B) were reactive more frequently in breast cancer samples than normal 
samples (p<0.05, chi-square test). Two peptide (C, D) were reactive more 
frequently in pancreatic cancer samples than normal samples (p<0.05, chi-square 
test). One peptide (D) was reactive more frequently in lung cancer samples than 
normal samples (p<0.05, chi-square test). A. PYDPEDPGQE in 7 viruses 
including XMRV showed high reactivity in 10.8%, 2.4%, 0%, and 0% 
respectively from   breast cancer samples, lung cancer samples, normal samples, 
and pancreatic cancer samples. The cutoff for high reactivity is 8.0. No difference 
was observed in lung cancer and pancreatic cancer samples. B. 
PRRRTPSPRRRRSQ from Hepatitis B virus showed high reactivity in 7.8%, 
3.6%, 1.2%, and 1.0% respectively from   breast cancer samples, lung cancer 
samples, normal samples, pancreatic cancer samples. Cutoff for high reactivity is 
7.0. C. Numbers on the top means the number of highly reactive samples in each 
group. C. HPKPPPPLPPSAPSL from Ab-MLV showed high reactivity in 0%, 
3.6%, 0%, and 4.2% respectively from breast cancer samples, lung cancer 
samples, normal samples, and pancreatic cancer samples. Cutoff for high 
reactivity is 7.0. No difference was observed in lung cancer and pancreatic cancer 
samples. D. TGAESEDSGDEGPSTRH from HHV-8 (or Kaposi Sarcoma virus) 
showed high reactivity in 0%, 3.6%, 1.2%, and 4.2% respectively from breast 
cancer samples, lung cancer samples, normal samples, pancreatic cancer samples. 
Cutoff for high reactivity is 7.0. Numbers on the top means the number of highly 
reactive samples in each group. X-axis is each sample while Y-axis is reactivity. 
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Acronyms; XMRV: Xenotropic MuLV-related virus, Ab-MLV: Abelson murine 
leukemia virus, HHV-8: Human herpesvirus 8. 
2.4 Methods 
2.4.1 Identification of putative tumor-associated viruses  
We took a bioinformatic approach to identify putative tumor-associated 
viruses by using EST sequences (see 2.2 Bioinformatic analysis).  
2.4.2 Selection of peptides for array analysis  
Basically, we made an effort to select the most immunogenic part of viral 
proteins from tumor-associated viruses. We used the B cell epitope program, 
BepiPred, from Immune Epitope Database (IEDB) supported by National Institute 
of Allergy and Infectious Diseases (NIAID) in order to select putative epitopes 
from viral proteins. The strict cutoff value, 1.3, allows us to have 0.96 of 
specificity and 0.13 of sensitivity.    
2.4.3 Samples  
Center for Innovations in Medicine, Biodesign Institute, Arizona State 
University has an existing IRB 0912004625. (i) 102 plasma samples from patients 
with breast cancer. (ii) 84 plasma samples from patients with lung cancer (iii) 95 
plasma samples from patients with pancreatic cancer. (iv) 162 plasma samples for 
control. 
2.4.4 Cancer Peptide Array  
The cancer chip is 21-up microarray containing 144 peptides that are 20 
amino acids long. 48 of them were our viral epitopes. This is customized 
microarray printed by AMI. 
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2.5 Discussion 
 Previous studies showed that we could detect viral transcripts in the 
sequencing data from infected cells (71-73). By using the approach of 
transcriptome analysis, our study is capable of obtaining the list of putative 
cancer-associated viruses that could be targeted by a vaccine. First, we detected 
viral transcripts in transcriptome data from cancer samples (Table 2.1). Some of 
them were found in multiple tumor samples, but not in any normal samples. Some 
of them were found more frequently in tumor samples than normal samples. 
Second, we observed the antibody reactions against possible epitopes from 
selected viral proteins by peptide array approach (Fig 2.3). Four of them showed 
high reactivity more frequently in cancer than in normal samples while several 
epitopes showed high reactivity in both tumor and normal samples. The presence 
of viral transcripts and immunogenicity of viral peptides in cancer samples 
supported the potential of viral peptides as vaccine antigens. 
 The same assumption from previous studies that infected cells contain 
nucleic acid of both host and infectious agent was used in this study. In fact, we 
could found the all viruses detected in Weber et al (74). However, our approach 
collected more information than any other studies. Basically, we used more 
sequences; recent EST database of more than 8 million sequences (December 
2010), which had been dramatically increased over 3-5 years. Larger data set 
allowed us to contrast their presence between tumor and normal libraries. 
Therefore, we were able to select several viruses that were more likely to 
associate with tumors.  
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 A surprising finding was that there was a differential expression among 
open reading frames (ORFs) in a virus (Figure 2.2) at least in the EST database. 
In other words, a particular virus with multiple ORF showed that some ORFs 
expressed more frequently in tumor than normal while some ORF expressed 
equally in both tumor and normal. Therefore, we could point out specifically what 
viral open reading frames (ORFs) were highly expressed. This information can 
guide us to make better selections of antigens. We suggest two possible 
explanations about different expression level of ORFs from a virus. First, there 
may be an intrinsic difference in expression level of each ORF. Critical ORF may 
have higher expression relative other ORFs. Second, the activity of certain ORF 
might be associated cancer development due to their functions. Therefore, we 
observe more mRNA of these critical ORFs in cancer than normal. 
 To have a more precise estimation, we need to have the four numbers; the 
numbers of cancer patients with/without a viral infection and the numbers of 
normal samples with/without a viral infection. If the ratio of a virus over non-
virus in cancer is higher than that in normal, that virus may be cancer-associated. 
This approach eliminates the concerns about contaminations in lab because those 
contaminations, presumably, will happen to both tumor and normal with same 
chance. Due to low coverage of EST data, the absence of viral transcripts did not 
guarantee a negative association. In near future, data from next generation 
sequencing technology will enable us to conduct this research with higher 
accuracy.  
  28 
 In summary, we have shown that the predicted epitopes from viruses 
detected in cancer transcriptome had antibody reactions in tumor samples. 
Considering the fact that it is often hard to prove causative viruses, if any, for 
cancer, the approach used in this study provides a good starting list of viruses that 
we can examine for vaccine antigens by using transcriptome data.  
2.6 Conclusion 
 Dr. Hausen who discovered the causation of cervical cancer by human 
papilloma virus (HPV) argued that it is worthwhile to search for new cancer-
associated viruses (71). What other viruses rather than HPV and hepatitis B virus 
(HBV) can cause or be associated with cancer? Transcriptome data from cancer 
patients will give us an opportunity to select putative cancer-associated viruses 
that we can test them for vaccine target. Our approach will be very useful to get a 
list of putative viruses when large amount of transcriptome data from cancer and 
normal samples are available. In addition, we can extend the same approach to 
search for bacterial or other pathogens in tumor sequence databases. This may be 
a reasonable pursuit as the infection of Helicobacter pylori, or H. pylori, shows 
some association with the incident of gastric cancer (77). Some bacteria 
sequences such as Erwinia amylovora ATCC 49946and Salmonella enterica 
subsp. enterica serovar Typhimurium str. LT2 were detected in this study. 
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CHAPTER 3  
FRAMESHITED CHIMERIC TRANSCRIPTS 
3.1 Introduction 
 The use of immunization to prevent disease is one of the most remarkable 
achievements of modern medicine. According to the Center of Disease Control 
and Prevention (CDC), there are 26 infectious diseases that are now preventable 
through prophylactic vaccination. The same principles are now being applied for 
the treatment of cancer. Despite conceptual promise, cancer vaccines have not 
been entirely successful, unlike vaccine against infectious diseases. The 
difficulties in preventing cancer by vaccination strategies are hindered by the 
selection of the appropriate antigens even though remarkable efforts have been 
made.  Recently, Cheever et al. outlined the suggested criteria for selecting the 
best antigens to be used in therapeutic vaccines. With these newly defined criteria, 
75 cancer antigens were prioritized (23).  However, almost all of the examined 
antigens are classified as self-antigens that may lead to post vaccination side 
effects such as autoimmunity. In addition, self-antigens run the risk of being non-
immunogenic or poorly immunogenic, thus incapable of breaking immune 
tolerance. One way to avoid the possible side effects associated with using self-
antigens as vaccine antigens would be to identify and test tumor specific antigens 
in a prophylactic setting rather than in a therapeutic setting. In a prophylactic 
setting, the immune system should not be in a suppressed state thus enabling a 
more robust and sustained a cellular (CD4+/CD8+ T cell mediated response) and 
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humoral (the B cell-mediated response to produce antibodies) response to the 
antigens used in cancer vaccines. 
 Among the many different types of mutations that occur while tumors 
develop, we are particularly interested in frame-shifted mutations because of their 
ability to generate neo-peptides. The use of FS peptides as tumor antigens has 
been previously mentioned and suggested by Townsend et al in 1994 (33). Since 
then, several reports have continued to support the use of FS peptides as cancer 
vaccine antigens since they have the ability to induce tumor-specific cell-
mediated immunity (37, 39, 78). The use of gene fusions as a source for 
generating FS peptides for a cancer antigens has not been extensively studied nor 
is there ample information regarding the frequency in which gene fusions’ 
chimeric transcripts create frame-shift peptides. Nonetheless, several gene fusions 
have been reported to play a significant role in malignant hematological disorders, 
Ewing’s sarcoma, and most recently have been shown to be useful as diagnostic 
and therapeutic targets for drugs such as Imatinib (79). Unlike malignant 
hematological disorders and Ewing’s sarcoma, gene fusions are less prevalent in 
epithelial-based cancers though this could be strongly contributed to the technical 
limitations of FISH and SKY cytogenetic analyses and the fact that these methods 
are not applicable as discovery tools. In order to quickly catalog cytogenetic 
rearrangements, the genomic coordinates for the genes that are involved in the 
translocation must be known. Recent non-cytogenetic technological 
advancements are now currently being employed for the discovery of gene 
fusions in solid tumors. Through the new technological approaches, cancer 
  31 
genetics are quickly being analyzed by outlier gene expression patterns, massively 
parallel paired-end sequencing and 454 transcriptome sequencing. These 
approaches have identified chimeric transcripts in prostate cancer, and 
adenocarcinomas of the lung and breast (59, 62, 80-84). Collectively gene fusions 
have been identified to occur within coding sequences (85) and have been shown 
to generate frame-shifted mutations (62, 80, 85, 86). Of note, confirmatory 
changes within the genomics regions that correspond to the newly rearranged 
fused genes are often not mentioned nor investigated. 
 With the increasing discovery of chimeric transcripts that results in the 
fusion of coding sequences from an upstream gene and part of an exon/intron 
from a downstream gene, it is becoming clear that these transcripts are abundantly 
present in cancer cells though their role, their importance and whether or not the 
transcripts get translated has not yet been determined. In this report we have taken 
a systematic approach to provide a comprehensive analysis of the presence of 
chimeric transcripts that are relevant to breast cancer. To quickly identify 
chimeric transcripts that may result in a frameshift neo-peptide we have written 
and tested an algorithm that is capable of nominating chimeric transcripts from 
publically available sequence databases and high-throughput sequencing data sets. 
In addition, we have determined the frequency and have predicted the potential 
epitope coverage these chimeric transcripts may present. Moreover, we have 
analyzed the various chimeric transcripts to determine if there are patterns of 
expression that reflect the stage of tumor differentiation. 
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3.2 Algorithm to identify FS chimeric transcripts 
 
Figure 3.1 Identification of EST derived from chimeric transcripts. Required 
conditions; i) (f-e) and (h-g) > 80, ii) |c-b| < 10, 3) 
 Using the stand-alone BLAST program, all EST sequences were aligned 
to RefSeq. We picked ESTs that aligned with more than 50-85 base pairs and had 
95-97% homology to RefSeqs that had been previously annotated by National 
Center Institute (NCI). We further filtered out our alignment data by eliminating 
the EST sequences that did not align to multiple RefSeqs or were aligned in the 
3’-5’ orientation. Lastly, we also eliminated the sequences that aligned with non-
coding sequence regions. The remaining EST sequences were then used to 
identify the chimeric transcripts. Only the ESTs that aligned to two or more 
distinct RefSeq in consecutive positions were considered to be potential 
candidates. To be defined as a coding chimeric transcript, the EST sequences had 
to be at least 100-170 bp long with sequence similarity greater than or equal to 
95%- 97% to the RefSeq. Also, the junction point between the two genes had to 
occur within the coding sequence of the upstream gene and orientation of the 
upstream gene alignment had to be in the positive (5’-3’) orientation. To eliminate 
false calls, all potential chimeric EST sequences had to be either present in more 
than one cDNA library or supported by three or more independent EST 
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sequences. In addition, chimeric transcripts were classified based on the relative 
position of two genes. Classification of types of chimeric transcript was based on 
relative position of two fusion genes on the chromosome. Specifically genes 
found on different chromosomes resulted in inter-chromosomal fusion while 
genes found in same chromosome were intra-chromosomal or read-through 
chimeric transcripts. Read-through chimeric transcripts resulted from two 
neighboring genes on same strand, otherwise intra-chromosomal. 
3.3 Results from EST analysis 
3.3.1 Putative FS chimeric transcripts 
 We used our semi-automatic alignment algorithm to identify frame-shifted 
chimeric transcripts from the available NCBI EST sequence database (Figure 1). 
Briefly, to support a chimeric transcript, one EST sequence must be able to align 
to two distinct RefSeqs continuously. Considering the EST database contains 
approximately 8M EST sequences, we outlined filtering criteria that were applied 
to eliminate irrelevant sequences. We discarded the EST sequences that did not 
align properly with annotated RefSeqs and ones that were from untraceable 
sources. The remaining 7M sequences were then examined for their ability to 
align with multiple RefSeqs. From this survey, there were 556,989 EST sequences 
that aligned with multiple RefSeqs. These 556,989 EST sequences supported 
2,394 EST chimeric transcripts from tumor and 2,944 EST chimeric transcripts 
from normal cDNA libraries while 104 EST chimeric transcripts were found in 
both tumor and normal. Collectively, these supporting EST sequences potentially 
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represent 5,234 non-redundant putative EST chimeric transcripts that aligned and 
created a continuous sequence that was composed of two different RefSeqs. 
Further analysis revealed that 1,133 out of 5,234 EST chimeric transcripts were a 
product of the reverse strand of the upstream gene combined with the forward 
strand of the downstream gene. Since this combination is not likely to occur 
naturally, we excluded these sequences from our analysis. The remaining 4,101 
EST chimeric transcripts candidates were then analyzed for the presence of a 
functional transcriptional coding sequence in the upstream gene. This step 
removed 1,693 EST chimeric transcripts. Last, we selected putative candidates 
out of the remaining 2,408 EST chimeric transcripts according to one of the 
following three criteria; i) the supporting EST sequences were found in two or 
more independent cDNA libraries, ii) the supporting ESTs were present in 
multiple copies within one library, or iii) the junction point within the newly 
identified EST chimeric transcript occurred exactly at the exon boundaries for 
both genes involved in the combination. Based on these criteria 170 EST chimeric 
transcripts were supported by two or more representative EST sequences found 
within multiple libraries, 22 EST chimeric transcripts were supported by three or 
more EST sequences within one library, and 304 EST chimeric transcripts were 
joined exactly at the exon boundaries for the two unique fused genes. The selected 
496 candidates were then examined for the potential to generate frame-shifted 
neo-peptides. 321 out of 496 chimeric transcripts from this analysis, if translated, 
would create a frame-shift peptide while the remaining 175 chimeric transcripts 
stay in frame. 
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Figure 3.2 Identification of frame-shifted coding gene fusions from EST 
sequences. Schematic above show the overall selection criteria used to identify 
frame-shifted EST chimeric transcripts in NCBI EST database. After filtering 
irrelevant ESTs, EST chimeric transcripts were defined by supporting EST 
sequences. Supporting ESTs of chimeric transcripts were identified by alignment 
condition; 85 bp or longer with 95% or more similarity or 50 bp or longer with 
97% or more similarity. From this analysis, 321 putative candidates were 
identified and were predicted to generate a frame-shifted peptide. T indicates 
tumor and N indicates normal. 
3.3.2 Experimental validation in breast cancer 
 Based on the informatic predictions, 321 out of 496 putative candidates, if 
translated, would generate frameshift peptides. For 230 out of 321 putative 
candidates, a neo peptide of 6 or longer amino acids would be generated thus the 
longer the peptide the more possible epitopes can be present. Additional 13 short 
FS peptides (from 1 a.a to 5 a.a) were added into the screening list because they 
were strongly supported by multiple numbers of EST sequences or libraries. 10 
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candidates out of 243 were removed since the overall length of the transcript was 
too short to design appropriate primers. To validate the presence of these 
predicted chimeric transcripts in breast tumors, we screened 50 breast cancer cell 
lines (see supplementary table) by RT-PCR using 233 different primer pairs. The 
initial validation was performed with four pools of 10-12 cDNAs that encompass 
fifty different breast cancer cell lines using standard PCR conditions in order to 
increase the chances of confirming the predicted candidates. The summary for all 
233 PCR reactions is shown in Figure 1B.  For 84 primer pairs, no products were 
amplified though this does not necessary mean that the chimeric transcripts do not 
exist, rather these transcripts might not be present in Breast Cancer cell lines since 
the initial informatic analysis utilized sequences from 40 different tissue types. 
For forty-nine primer pairs a single PCR product that corresponded to the 
expected size was amplified of which thirty-eight were confirmed by sequencing. 
For 72 primer pairs, multiple products were amplified however 34 reactions had 
the expected product size within the various bands amplified and thirty-eight 
reactions did not contain the correct expect product. Sequence confirmation was 
obtained for seven out of the 34 reactions that had the correct expect size within 
various bands.  The remaining twenty-eight out of the 321 candidates produced a 
single PCR product that did not match the expected size. For this group, we 
sequenced 6 PCR products that were the predominant band and close in predicted 
size; one additional candidate was confirmed. 
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Figure 3.3 Chimeric Transcript PCR Validation Strategy. Shown here is the 
summary for 233 chimeric transcript PCR reactions. Using Pools of cDNA from 
various breast cancer cell lines, the fidelity of the primers was determined. Shown 
by color is the type of PCR product that was observed. In bold within each color 
is the number of chimeric transcripts that were sequenced confirmed. 
 Based on all of the sequencing, we identified new combinations of exons 
that the primers would amplify. For example, exon 13 of NAIP was expected to 
fuse with exon5 of OCLN. However, our designed primer amplified two 
predominant bands; the expected product and a smaller product as a result of the 
forward primer annealing to sequences within exon 12 of NAIP. Sequencing of 
the unexpected smaller band revealed that exon 12 of NAIP, instead of exon 13, 
fused with exon 5 of OCLN. By sequencing the unexpected size, but the 
predominant PCR products, three iso-forms were validated in addition to the 
original expected chimeric transcripts. Collectively, through this approach, we 
validated 48 FS chimeric transcripts that when classified by the chromosomal 
location of the genes involved in the fusions, 13 are intra chromosomal, 34 are 
read-through, and 1 is inter-chromosomal. Of note, two chimeric transcripts that 
our analysis identified have also previously been described in the literature; 
BCAS4-BCAS3, MDS1-EVI1 (Table 3.1). 
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Table 3.1 Validated Frame-shifted chimeric transcripts. Chimeric transcripts 
were validated by RT-PCR and confirmed by sequencing. All transcripts have 
predictive neo-peptides by frame-shifted mutation at downstream genes or by 
translated from 5’UTR region. The average length of frame-shifted neo-peptide is 
32.7 amino acids with range of 1 amino acid to 204 amino acids. 
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3.3.3  Frequency of FS chimeric transripts 
 In order to establish the frequency for the chimeric transcripts, the 48 FS 
chimeric transcripts validated in the initial pool screening were screened across all 
50 breast cancer cell lines individually by RT-PCR (see Figure 3.4). Frequencies 
varied from 2% to 98%. From these results, 17 out of 48 were not detected in the 
non-cancerous cell line, MCF-10A. Due to insufficient amount of cDNA from 
primary tumor samples, 35 out of 48 FS chimeric transcript were screened in 57 
breast tumors. Frequencies in primary samples ranged from 0% to 97%. In 
addition, only 3 out of the 48 chimeric transcripts that were present in cell lines 
were absent in primary samples. Among the 57 primary samples, 3 samples 
consisted of normal breast tissues of which 12 out of 35 chimeras were not 
detected. Due to low RNA yields and the difficulty in obtaining RNA material 
from healthy breast tissue only 22 chimeric transcripts were screened in both the 
MCF-10A and in 3 primary normal breast tissue samples. The remaining 16 
chimeric transcripts were only screened in the MCF10A cell line. By 
chromosomal location classification, read-through transcripts were the most 
frequent followed by intra-chromosomal and inter-chromosomal. Though the 
majority of transcripts identified are read-through, some intra-chromosomal 
chimeras such as GFOD-C6orf114 and inter-chromosomal gene fusion, TRIM61 
– FARSB (data not shown due to in-frame mutation) had high frequencies of 
86.1% to 71.4% respectively with about 90% precision. In terms of precision of 
our RT-PCR screenings, we observed some discrepancies in the results of RT-
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PCR from samples of same source. cDNA from cell lines yielded more robust 
RT-PCR results than from primary samples.    
 
Figure 3.4 The frequency of chimeric transcripts in breast cancer. This graph 
shows the frequency of 35 FS chimeric transcripts that were examined in both cell 
lines and patients. The presence of chimeric transcripts in each sample was 
determined by RT-PCR. The expected size of amplified band was considered as a 
positive. 10% of them were subject to sequencing to confirm. Gray bar indicates 
their absence in non-cancerous cell line (MCF-10A) while  indicates their 
absence in three normal breast tissues. Not all chimeric transcripts were screened 
in normal samples (see details in supplementary table). 
3.3.4  Potential epitopes with population coverage 
 To see the potential MHC coverage that the chimeric transcripts may have 
if translated and used as cancer vaccine antigens, we examined all possible 
epitopes that would be represented by the frame-shifted peptides. The length of 
the predicted FS peptides ranged from 1 to 204 amino acids with the overall 
average length being 32 amino acids long. Using 10 amino acids of the upstream 
genes from the junction plus the full length of downstream FS peptide, all 
possible MHC I potential epitopes were predicted. For the 48 chimeric transcripts 
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that generate a FS neo peptide, 1,317 unique epitopes that are able to bind to 35 
different MHC alleles were identified. For example the FS peptide, from the 
chimeric transcript called DDIT – MARS is 138 amino acids in length, is able to 
generate epitopes for 27 different MHC alleles. However, there were a few 
chimeric transcripts such as RMND5A - ANAPC1 that did not contain any MHC 
I binding epitopes. Through this analysis, when we evaluate all of the FS antigens, 
the coverage regarding the various populations within the United States are as 
followed: 99.66% for Caucasians, 98.22% for Hispanic, 96.5% for Asian Pacific 
Islanders, and 92.92% for African American. Allele frequencies were adjusted 
using the relative frequency of the individual chimeric transcripts. In addition, we 
made an effort to identify the minimum number of antigens that would have the 
largest population coverage by including only the top five most frequent HLA 
alleles found within individual ethnic groups. Based on this analysis, 85.56% of 
Caucasians from the United States would benefit from a vaccine that contained 
seven neo-peptides from the following chimeric transcripts; BOLA2-SMG1, 
GFOD1-C6orf114, ELAC1-SMAD4, TIMM23B-LOC100132418, C22orf39-
HIRA, MDS1-EVI1 and DDIT3-MARS whereas  75.93% of Hispanics in the 
USA would benefit from a vaccine that contained 4 antigens (BOLA2-SMG1, 
GFOD1-C6orf114, ELAC1-SMAD4, DDIT3-MARS). Other combinations that 
consisted of 6 antigens (GFOD1-C6orf114, RRM2-C2orf48, TIMM23B-
LOC100132418, MDS1-EVI1, DDIT3-MARS, C1QTNF6-IL2RB) or a pool of 
five antigens (C20orf29-VISA, GFOD1-C6orf114, LOC100129406-
CTTNBP2NL, MDS1-EVI1, DDIT3-MARS) would protect 82.5% of Asian 
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Pacific Islanders and 63.08% of African Americans in the USA respectively. In 
conclusion, if a cancer vaccine was limited by the number of antigens that could 
be used at one time, 10 FS antigens would be effective in more than 60% of the 
population regardless of ethnicity. 
Table 3.2 Population coverage of antigens from chimeric transcripts. A. 
Shows the number of possible MHC-binding epitopes from selected chimeric 
transcripts. Entire data is provided in Supplementary table 1. Numbers in ( ) 
means the epitopes derived from junction between upstream 10 amino acids and 
FS peptide. * indicates the length of FS peptides. B. We project the population 
coverage based on a group of selected antigens rather than all 48. Overall, about 
10 antigens are able to cover more 60% of the population in the USA regardless 
of ethnicity or HLA types. 
A. 
 
B. 
 
3.3.5  FS chimeric transripts in mouse and dog 
 To see whether these FS chimeric transcripts can be tested in animal 
models such as mice and dogs, I examined the homologous genes involved in our 
putative chimeric transcripts, in mouse and dog by using BLAST program. I 
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assumed that there might be possible corresponding mouse chimeric transcripts 
corresponding to human ones when both genes in fusion have homologous genes 
in mouse. The same principle was applied to dog. 64 mouse chimeric transcripts 
were selected by the homologous gene search for RT-PCR screening. 14 mouse 
chimeric transcripts were detected and sequence confirmed at least one of 10 
mouse cell lines (Table 3.3). 
Table 3.3 The list of validated mouse chimeric transcripts. 13 mouse 
transcripts were validated in 10 mouse cell lines. Peptide marked with * were 
detected in * sample at mRNA level when multiple peptides were detected. 
 
 24 predicted dog chimeric transcripts were screened in 22 cancer samples 
from melanomas, osteosarcomas, lymphosarcoma, hemangiosarcoma, breast, 
mast cell tumor, transitional cell carcinoma, and thyroid adenocarcinoma as well 
as 13 normal samples from various tissue types. 8 chimeric transcripts were 
validated in dog cancer samples (Table 3.4).  
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Table 3.4 The list of validated dog chimeric transcripts. 
 
3.4 Methods 
3.4.1 Data Sets and Algorithm 
To identify potential putative chimeric transcripts, that when translated 
would result in a frame-shifted neo-peptide; we targeted two publically available 
datasets and applied an algorithm that was used to identify chimeric transcripts. 
Specifically, we used the sequences found within the Expressed Sequence Taq 
(EST) library (51) and the Human RefSeq database (76) from the National Center 
for Biotechnology Information (NCBI). Using the stand-alone BLAST program, 
we aligned all EST sequences to RefSeq. We picked ESTs that aligned with more 
than 50-85 base pairs and had 95-97% homology to RefSeqs that have been 
previously annotated by National Center Institute (NCI). We further filtered out 
our alignment data by eliminating the EST sequences that did not align to 
multiple RefSeqs or were aligned in the 3’-5’ orientation. Lastly, we also 
eliminated the sequences that aligned with non-coding sequence regions. The 
remaining EST sequences were then used to identify the chimeric transcripts. 
Only the ESTs that aligned to two or more distinct RefSeq in consecutive 
positions were considered to be potential candidates. To be defined as a coding 
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chimeric transcript, the EST sequences had to be at least 100-170 bp long with 
sequence similarity greater than or equal to 95%- 97% to the RefSeq. Also, the 
junction point between the two genes had to occur within the coding sequence of 
the upstream gene and orientation of the upstream gene alignment had to be in the 
positive (5’-3’) orientation. To eliminate false calls, all potential chimeric EST 
sequences had to be either present in more than one cDNA library or supported by 
three or more independent EST sequences. In addition, chimeric transcripts were 
classified based on the relative position of two genes. Classification of types of 
chimeric transcript was based on relative position of two fusion genes on the 
chromosome. Specifically genes found on different chromosomes resulted in 
inter-chromosomal fusion while genes found in same chromosome were intra-
chromosomal or read-through chimeric transcripts. Read-through chimeric 
transcripts resulted from two neighboring genes on same strand, otherwise intra-
chromosomal. 
3.4.2 Cell lines and tissue samples 
The 50 Human Breast cancer cell lines were obtained from the American 
Type Culture Collection (ATCC) (see supplementary table B.4) and were grown 
according to recommendations. Human breast cancer tissue specimens were 
acquired from Mayo Clinic after appropriate patient consent and approval of the 
Mayo Clinic Institutional Review Board.  All specimens were coded and 
anonymized. 
  46 
3.4.3 Primer design and RT-PCR validation 
Total RNA was extracted from breast cancer cell lines and primary breast 
tissues using the TRIzol LS reagent (Life Technologies, Carlsbad, CA) following 
the manufacturers protocol. RNA integrity was determined by gel electrophoresis 
and concentration was determined by measuring absorbance at 260/280 on the 
Nano-drop (NanoDrop Products, Wilmington, DE). cDNA was prepared by using 
the SuperScriptTM III First-Strand Synthesis SuperMix (Life Technologies, 
Carlsbad, CA) that includes random hexamers and oligo dT’s following the  
manufacturer’s recommended protocol. cDNA integrity and quality were assessed 
by performing a β-actin control PCR. End Point PCR primers for each chimeric 
transcript were designed using Primer3 (87) so that the forward and reverse 
primer both binds 80bp to 280bp upstream/downstream from the junction point. 
End-point PCR reactions using approximately 25 ng of cDNA, reagents from 
(Life Technologies, Carlsbad, CA) and 35 cycles were performed using 
Mastercycler ep gradient S (Eppendorf, Hamburg, Germany). PCR products were 
analyzed on 1.5% agarose gels. PCR products were purified and sequence 
confirmed by Applied Biosystems 3730 (Life Technologies, Carlsbad, CA). 
3.4.4 Epitope prediction and population coverage 
Predicted frame-shifted peptides including 10 amino acids from the 
upstream genes were used to analyze all possible epitopes. By using the Immune 
Epitope Database and Analysis Resource (IEDB) (88) that is provided by the 
National Institute for Allergy and Infectious Diseases (NIAID), we were able to 
obtain a list of all possible epitopes that would be produced from validated 
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chimeric transcripts with their respective population coverage. First, epitopes 
binding to MHC class I were identified by a prediction algorithm tool from IEDB. 
We selected artificial neural network (ANN) as a prediction method according to 
IEDB evaluation. NetMHC (89) was then used in IEDB for ANN implementation. 
The prediction of peptide-MHC binding was based on artificial network trained 
on data for 55 MHC alleles and position-specific scoring matrices (PSSMs) for 67 
additional HLA alleles. An epitope was considered positive when the IC50 < 500 
because most known epitopes have high (IC50 < 50) or intermediate (IC50<500) 
affinities. After obtaining all possible epitopes, we then made a hypothetical 
projection about population coverage by using another analysis tool in IEDB. This 
tool was designed to calculate the proportion of individuals based on HLA 
genotypic frequencies (from dbMHC, NCBI) (90). The linkage equilibrium 
between different HLA alleles was assumed in their calculations. We found that 
chimeric transcripts were completely independent of each other by chi square test. 
Both frequencies of HLA genotype and chimeric transcripts were considered for 
population coverage. Original HLA genotypic frequencies were adjusted by the 
frequency of chimeric transcript to generate the epitopes to bind the HLA allele. 
We attempted to find the fewest number of chimeric transcripts which would 
correspond to an effective FS peptide vaccine for the greatest percentage of the 
human population.  In order to achieve this goal, we needed to figure out the best 
set of chimeric transcripts which could protect the maximum portion of the 
population depending on the frequency of these chimeric transcripts and the 
frequency of MHC alleles which bind to them.  There are many possible 
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combinations of MHC alleles, chimeric transcripts, and cell lines.  In order to 
reduce the complexity of searching through all of these possible combinations to 
find the optimum number of chimeric transcripts needed for a vaccine, we 
considered only the 5 most frequent MHC alleles in the human population.  Once 
these frequent MHC alleles were selected, we determined the combination of 
chimeric transcripts which bind to most of these MHC molecules.  The percentage 
of the population which would be protected by these chimeric transcripts and 
appropriate MHC alleles was then calculated by using “Population coverage 
calculation” program (90). In this program, average population coverage by a set 
of epitopes is generated by the following numbers; projected population coverage, 
average number of possible epitopes by the population.  
3.5 Discussion 
 Selecting and determining the appropriate antigens to be used in a cancer 
vaccine is one of the most critical and time consuming steps in the development 
process of a cancer vaccine. Here we explore the concept of using FS peptides 
that are generated from gene rearrangements and/or chimeric transcripts as the 
sources of antigens to be used in a prophylactic cancer vaccine. The screening of 
publically available sequence data allowed for the rapid identification of chimeric 
transcript that if translated would produce novel neo-peptides. Through this 
approach, 48 FS chimeric transcripts out of the called 496 putative candidates 
derived from the analysis of EST Db were identified and validated in breast 
cancer cell lines and primary tumors. Out of the 48 confirmed candidates 2 
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chimeric transcripts, BCAS4-BCAS3 (breast) and RBM14-RBM4 (prostate) have 
been previously been identified by 454 sequencing transcriptome sequencing and 
reported by Maher et al. (61, 81). With the increasing availability of high 
throughput sequencing data, the development of an algorithm screening process 
may expedite the discovery of neo-peptides that are produced from chimeric 
transcripts that are generated by either trans-splicing or chromosomal 
rearrangement mechanisms. Such candidates could be then be used as cancer 
vaccine antigens and novel therapeutic targets. 
 For the last several years, the cancer research community has been 
interested in understanding the role that gene fusions play in leukemias since the 
identification of the BCR/ABL gene fusions has been so successful for the 
treatment of chronic myeloid leukemia (CML). For solid tumors (prostate, breast 
and skin cancers) the search for gene fusions has recently expanded as a result of 
high profile sequencing projects (58, 80, 81, 85). The number of gene fusions has 
been doubled in the literature over the past four years, but the overall frequency 
for each gene fusion has not been described nor evaluated across different solid 
tumor types. Currently there are over 70 different gene fusions that have been 
reported for more than 60 different cancer types. Included in this list are 78 gene 
fusions that have been found in breast of which 33 are considered FS chimeric 
transcripts (61, 62, 80, 85, 86).  In order to make a prophylactic cancer vaccine or 
to truly understand if the presence of gene fusions is random or a controlled 
process, identifying the frequencies would help evaluate if chimeric transcripts 
are a result of a driver or passenger mutations as a result of the combination of 
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genes involved. Using the criteria that were recently described by to make a 
prophylactic cancer vaccine or to truly understand if the presence of gene fusions 
is random or a controlled process, identifying the frequencies would help evaluate 
if chimeric transcripts are a result of a driver or passenger mutations as a result of 
the combination of genes involved. Using the criteria that were recently described 
by Bozic et al. (91), FS chimeric transcripts would be considered as a driver 
mutation since protein sequences are affected by a frame-shift mutation. 
However, the data present in this study does not fully support the driver mutation 
phenomenon because the majority of the chimeric transcripts are present in too 
high of frequency to be considered a drive mutation. Therefore, by definition, the 
FS chimeric transcripts in this study could be considered passenger mutations as a 
result of the overall genomic instability of the tumor. The frequencies for these 
target antigens will be critical to the development of a prophylactic cancer 
vaccine. For example, the prevalence of mutation will aid in determining the 
number of antigens that would be needed to protect at least 70~80% of the 
population. 
 Epitopes from antigens will elicit immune response only when it is 
presented to immune system by major histocompatibility complex (MHC) 
molecules. Therefore, we can estimate the efficacy of the antigens produced from 
these chimeric transcripts based on MHC binding epitopes. As we expected, long 
neo-peptides from frame-shifted mutations, relative to substitution, have a rich 
pool of epitopes. 46 of HLA-A*0201 epitopes were presented in 48 frame-shifted 
mutations while 241 of HLA-A*0201 epitopes were presented in 1,307 mutations 
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according to Segal et al (92). This clearly shows the advantage of using FS 
peptides as a vaccine antigen in covering a greater proportion of population. 
Another discover of interest is the observation that several HLA alleles from the 
48 FS peptides such as HLA A*0101, HLA A*2601, HLA B*4402 and HLA 
B*5101 lacked their binding epitopes. In general, frame-shifted chimeric 
transcripts will be ideal antigens according to nine criteria suggested by Cheever 
et al.; i) therapeutic function, ii) immunogenicity, iii) oncogenecity, iv) 
specificity, v) expression level and % positive cells, vi) stem cell expression, vii) 
No. patients with antigens-positive cancers, viii) No of epitopes and ix) cellular 
location of expression (23). Frame-shifted chimeric transcripts may be even better 
antigens in terms of epitope presentation, as we showed in this study, by 
generating longer neo-peptides. In addition, many of our FS chimeric transcripts 
were detected in multiple samples and some of them could be tumor-specific even 
though we need to screen more normal samples to validate it. Furthermore, we 
validated the corresponding chimeric transcripts in mouse and dog by homology 
search that could be tested for immune response. Considering no frame-shifted 
peptides had even been evaluated in their study of 75 antigens, it is worth 
examining the potential of FS chimeric transcripts as a cancer vaccine antigen. 
3.6 Conclusion 
Gene fusions in cancer have been proven to be effective diagnostic and 
therapeutic targets. Here we show the potential of chimeric transcripts as 
appropriate vaccine antigens. As we studied the transcriptome, we need to take 
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next step in investigating whether or not the protein is translated from these 
chimeric transcripts. Several studies have shown the production of a chimeric 
protein stemming from in-frame gene fusion (93-95). As a next step, we will 
search corresponding FS peptides from these chimeric transcripts in tumor and 
normal cells. Finally, detected peptides will be subject to immunological tests by 
using animal models. As observed in other studies (96), differential expression 
levels of chimeric transcripts between tumor and normal cells may provide us 
with clues regarding the presence of chimeric proteins. This study provides an 
insight into utilizing chimeric transcripts as a first step in a broader effort to 
develop a cancer vaccine from frame-shifted peptides based on their frequencies 
and possible epitopes.  
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CHAPTER 4  
PATTERNS IN CHIMERIC TRANSCIRPTS 
4.1 Introduction 
 The list of about 770 gene fusions from the literatures and our study was 
obtained and stored as a table. One interesting observation was that some genes 
appeared multiple times in the table. Therefore, I wondered whether these gene 
fusions are totally random events or not. What patterns could we find from these 
gene fusions? To search the patters in gene fusions, I collected the information of 
gene fusions from public data base and our study and analyzed them by using 
program of complex network analysis, Cytoscape (97). Three patterns were 
detected in our study; interconnected network, dominant exon combination, and 
dominant iso-forms. These patterns in gene fusions enable us to do cost-effective 
targeted sequencing to establish the frequency of aberrant transcripts with a 
higher accuracy. 
4.2 Gene Fusions in the Literatures  
 The information regarding gene fusions or chimeric transcripts was 
retrieved from two sources; Mitelman Database (98) and the Catalogue Of 
Somatic Mutations In Cancer (COSMIC), Sanger Institute (99). 588 distinctive 
gene fusions were collected from Mitelman Database (July, 2010). 96 distinctive 
gene fusions with their position of junction between two genes were obtained 
from COSMIC (CosmicFusionExport_v51).  In addition, we retrieved data on 
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gene fusions that had not been deposited into the two former databases from more 
recent publications.  
4.3 Patterns in Gene Fusions 
 A total of 770 distinctive genes involved in 698 gene fusions as collected 
from literatures and our analysis were used for pattern analysis. We used a 
program called “Cytoscape” (97) to draw connections among genes according to 
their gene fusions. 
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4.3.1 Interconnected networks of chimeric transcripts 
 
Figure 4.1 Network of gene fusions. Each node indicates a gene and edge 
connects nodes when two nodes (or genes) form a gene fusion. A. The largest 
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single cluster was derived from 506 gene fusions. B and C. Small clusters and 
separate gene fusions. 
 Interestingly, 506 gene fusions (72.5%) were connected in one large 
cluster because many of them the shared the same genes as partner (Figure 4.1). 
How about gene fusions detected in solid tumors? 77 out of 309 (24.9%) gene 
fusions in solid tumors formed a single clusters. 125 gene fusions (40.5%) 
belonged to 7 clusters, which comprised of more than 5 members (Figure 4.2).  
 
Figure 4.2 Network of gene fusions found in solid tumors. 7 clusters have more 
than 5 members each. The largest cluster consists of 77 gene fusions. 
 At an individual level, some genes combined with multiple genes as 
partners in their gene fusions (see Figure 4.3). By the relative position, 5’ or 3’, 
there consisted of two types; anchor upstream and anchor downstream. 43 genes 
(17% of 247 upstream genes of fusions) at the 5’ position of gene fusions 
combined at least two or more gene at 3’ position. 15 of them fused with more 
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than 5 genes as downstream partners. Myeloid/lymphoid or mixed-lineage 
leukemia (MLL) joined with 63 different genes at its downstream. 76 genes (20% 
of 371 downstream genes of fusion) joined more than one gene. B-cell 
CLL/lymphoma 6 (BCL6) has 22 different upstream gene as a partner. 13 of 76 
genes have more than 5 partners.  
 
Figure 4.3 The multiple gene fusions with a shared gene. Based on the position 
of anchor genes, there are two types; anchor upstream and anchor downstream. 42 
anchor upstream generated 377 gene fusions while 76 anchor downstream yield 
287 gene fusions. 
4.3.2 Dominant Exon combination 
 A total of 16 genes formed gene fusions with 10 or more partners. 12 
genes at upstream position joined 10 or more downstream genes to generate gene 
fusions while 4 genes combined with 10 or more upstream genes to produce 
chimeras. We were able to retrieve exon information of gene fusions related to 
EWSR1, ETV1, ALK from COSMIC data. In the case of ETV1, 6 out of 13 exons 
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combined with 6 different genes. However, EWSR1 and ALK showed that a 
particular exon dominantly combined with other genes out of 19 and 29 exons 
respectively from EWSR1 and ALK (Figure 4.4). In most cases, exon 8 of 
EWSR1 joined to other genes to form gene fusions. Only exon 20 of ALK was 
involved in the combination with other genes.  
 
Figure 4.4 Dominant exon combinations. An exon8 combined with most of 
downstream partners among 19 exons from EWSR1. Out of 29 exons from ALK, 
only exon20 was involved in gene fusions with 10 different genes. 
4.3.3 Dominant iso-forms of chimeric transcripts 
  42 gene fusions were reported to have iso-forms according to information 
extracted from the COSMIC database. Therefore, I was interested if there was a 
bias in the participation of iso-forms in gene fusions. In fact, 18 gene fusions had 
a dominant iso-form in general. For instance, Table 4.1 showed the dominant iso-
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forms of gene fusion between TMPRSS2 and ERG from three studies. In all three 
studies, the combination between exon 1 of TMPRSS2 and exon 5 of ERG was 
the most frequent one (100-102). In the case of two gene fusions, COL1A1-
PDGFB and ASPSCR1-TFE3, there was a dominant iso-form in each case, but 
each case had different dominant iso-form. 22 gene fusions did not have any 
dominant iso-form. 
Table 4.1 Iso-forms of TMPRSS2-ERG. TMPRSS2 combined with ERG by 
means of several different exon combination according to three studies. However, 
all three studies showed that the combination between exon 1 of TMPRSS2 and 
exon 5 of ERG was most frequent in comparison to other combinations. 
 
4.4 Discussion 
 In this study, we have shown that some combinations between two genes 
in chimeric genes are not random events based on observed patterns. First, there 
are a set of genes that combined with many other genes. Second, a particular 
single exon among all exons in a gene mainly contributes to generate a gene 
fusion. Third, a dominant combination of exons between two genes existed in 
5' Gene Last Exon 3' Gene First Exon Percentage Total # sample Sample Reference
TMPRSS2 1 ERG 6b 0.07
TMPRSS2 3 ERG 6b 0.07
TMPRSS2 1 ERG 5 0.27
TMPRSS2 1 ERG 2 0.07
TMPRSS2 1 ERG 6b 0.01
TMPRSS2 4 ERG 5 0.03
TMPRSS2 1 ERG 3 0.06
TMPRSS2 3 ERG 6b 0.03
TMPRSS2 1 ERG 5 0.45
TMPRSS2 3 ERG 5 0.13
TMPRSS2 1 ERG 2 0.1
TMPRSS2 4 ERG 2 0.03
TMPRSS2 3 ERG 2 0.04
TMPRSS2 3 ERG 6b 0.15
TMPRSS2 1 ERG 3 0.15
TMPRSS2 1 ERG 5 0.59
TMPRSS2 3 ERG 5 0.15
TMPRSS2 1 ERG 2 0.07
15 Yoshimoto et al.
67 Wang et al.
27 Jhavar et al.
prostate, 
carcinoma-
adenocarcinoma
prostate, 
carcinoma-
adenocarcinoma
prostate, 
carcinoma-NS
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many gene fusions. These patterns are unlikely to be random based on a statistical 
test. 
 What does make these patterns? We suggested two hypothetical 
mechanisms; 3 dimensional configuration of chromosomes and expression pattern 
of two genes. It is a reasonable assumption that gene fusion is more likely to 
happen where two genes located close in space together. Recently published 
papers support this reasoning. Our second explanation is that the two genes of the 
fusion are not normally expressed in high level together, but they are highly 
expressed together in tumor. Therefore, two genes would have a higher 
probability to combine together by chance. This idea may be tested by using 
expression data generated by DNA microarray or RNA-seq.  
 The knowledge about these patterns allows us to perform targeted 
sequencing/resequencing to identify the putative gene fusions for cancer antigens 
efficiently. The genes that have many partners will be of primary targets and exon 
information helps us to design probes. By this approach, we can find new gene 
fusions derived from the targeted genes as well as accurate frequencies of targeted 
gene fusions. This information may enable us to select the better candidates as 
vaccine antigens. The pattern of fusions may also have a tumor bias, so be useful 
in diagnostics.  
4.5 Conclusion 
 The knowledge about these patterns allows us to perform targeted 
sequencing/resequencing to identify the putative gene fusions for cancer antigens 
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efficiently. The genes that have many partners will be of primary targets and exon 
information helps us to design probes. By this approach, we can find new gene 
fusions derived from the targeted genes as well as accurate frequencies of targeted 
gene fusions. The obtained information enables us to select the better candidates 
as vaccine antigens. The pattern of fusions may also have a tumor bias, so be 
useful in diagnostics.  
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CHAPTER 5  
CODING MICROSATELLITE DNA 
5.1 Introduction 
 Cancer is a genetic disease, resulting from the sequential accumulation of 
genetic alterations (103). Common characteristics of tumor (104) are  the basis to 
speculate that there are pivotal genetic alterations to induce a tumor. The targeting 
of these pivotal mutations brought us remarkable outcomes in cancer treatment 
like imatinib (105). The advent of high-throughput sequencing technology enables 
us to detect more tumor specific mutations as new drug targets by systematic 
sequencing of tumor transcripts. Recent large-scale sequencing studies show that 
the prevalence and patterns of somatic mutations are substantially different 
between samples even though there are more mutations involved in tumor than 
previous estimation (106, 107). These observations may indicate the absence of 
prevalent and consistent mutations over different cancer types at the DNA level 
even though there might be the prevalent tumor-specific alternative splicing or 
fusion transcript from translocations, which could not be detected by the way two 
studies referenced. 
 Simple repeat sequences, microsatellite (MS) DNAs, may offer another 
source of cancer mutations because of their high mutations rate. In addition, 
genomic instability, the characteristics of cancer, promotes the mutation events at 
MS DNAs during tumor development. Therefore, we may expect that common 
Indels occurr at coding MS DNA across different cancer samples. A recent large-
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scale sequencing study of cancer genome done by Greenman et al. (107) found 11 
mutations in multiple samples and five of them were FS mutations from coding 
MS DNAs. 
 Frameshift (FS) mutation from coding MS DNAs by insertion/deltion 
(Indels) is a potential source to generate tumor specific antigens due to their 
extensive polymorphism and frequent occurrence in the human genome. Several 
studies have already shown the potential of FS peptides from coding MS DNAs as 
novel targets of cancer treatment (35, 39, 46). FS peptides from MS DNAs will be 
good cancer vaccine antigens because they are likely to be immunogenic unlike 
one amino acid change from substitutions. These data support the feasibility of 
this approach in terms of immunogenicity and prevalence of FS peptides. 
In this study, we tried to detect the tumor-specific mutations in coding MS 
DNAs by using the huge amount of EST data and RNA-seq data. Based on our 
definition of MS DNA, we can count the frequency of Indels in coding MS DNAs 
in tumor and normal. Through the analysis of transcriptome, we characterized the 
Indels in coding MS DNAs by several factors; length of repeat, repeat unit, tumor 
types, and allele. Finally, we selected putative cancer vaccine antigens based on 
the characteristics of Indels in coding MS DNAs. 
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5.2 Bioinformatic Approach 
5.2.1 Definition of microsatellite DNA  
What is a microsatellite DNA? In general, tandem sequence consists of 
repeating units of 1-6 base pairs in length (i.e. AAAAAAA, ACACACACACAC, 
and AGTAGTAGTAGTAGT). However, there is no real consensus about what is 
microsatellite DNA in terms of number of iterations and degeneracy (43).  
 
Figure 5.1 An example of deletion in coding MS DNA. The gene called TGFbII 
has eight As in a raw in the coding region. One deletion of A results in a frame-
shifted peptide, TVGRPHISC. 
Therefore, I constructed my own functional definition of MS DNA. I 
focused on mono nucleotide (mono) MS DNA since established genes, TGFβ-RII, 
BAX, hMSH3, hMSH6, and IGFIIR , as a maker for the microsatellite instability 
(MSI) colorectal cancer genes are mono-nucleotides. First, we do not allow any 
degeneracy, but set seven as minimum number of iterations. The minimum 
number of iterations was determined based on distribution of the number of MS 
DNAs (Figure 5.2). Basically, we do not want to investigate either too many MS 
DNA or few MS DNA.  
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Figure 5.2 The distribution of the number of MS DNA according to the 
minimum number of repeating unit. We checked the number of coding MS 
DNA by changing the minimum number of repeat units for being coding MS 
DNA.  8 as a minimum yielded relatively quite few (1,912) while 6 as a minimum 
yielded relatively quite many (21,012). Therefore, we selected 7 as minimum 
repeating for MS DNA, which gave us 7,471 MS DNA. 
 For the mono MS DNA, there were 4,563 genes (about 23% of total 
human genes) that contained at least one MS DNA in the coding region. Total 
number of MS DNA was 10,069 because 1,771 mRNA of 1,203 genes had more 
than one MS DNA. Seven genes including BRCA2 carry even 10 or more MS 
DNA in their coding regions (Table 5.1). 
 
Table 5.1 The list of genes that carry 10 or more coding MS DNAs. 
Gene Definition NCBI RefSeq Number of coding MS 
CCDC168 
coiled-coil domain containing 
168 NM_001146197.1 14 
FSIP2 fibrous sheath interacting 
protein 2 
NM_173651.2 13 
CEL carboxyl ester lipase NM_001807.3 13 
DNAH14 dynein, axonemal, heavy NM_001373.1 12 
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chain 14 
LMTK3 lemur tyrosine kinase 3 NM_001080434.1 10 
ANKRD12 ankyrin repeat domain 12 NM_015208.4 10 
BRCA2 breast cancer 2, early onset NM_000059.3 10 
 
 
Figure 5.3 The distribution of coding mono MS DNA. (a) The MS DNA with 
repeating unit of A was the most common while one with T repeating unit is least 
common. (b) The shorter MS DNAs are more frequent than the longer ones. In 
fact, 79% were 7 bp and 16% were 8 bp, therefore theses two length covered 
95%. The longest is 18 bp. 
5.2.2 Algorithm to identify Indels at coding microsatellite DNAs 
 Basically, we aligned qualified (see method) transcripts with human 
mRNA reference sequences that have MS DNA in their coding sequences by 
  67 
using BLASTN without repeat masking option. Therefore, we can align transcript 
sequences with MS DNAs, which were usually masked due to their low sequence 
complexity. Among the selected EST sequences, we identified transcript 
sequences derived from the coding MS DNA of reference sequences according to 
their coordination. Simply, we identified the alignment of transcript sequences 
with reference sequences that covered MS DNA with at least 3 bp of both 
flanking sides by using four numbers; starting and end position of reference 
sequence in the alignment and starting and end position of reference sequence and 
end position of coding MS DNA in the reference sequence. Only insertion / 
deletion (Indels) and substitutions within the MS DNA were counted while any 
other mutations outside of MS were not counted for this analysis. We counted 
how many repeat units were added or deleted in the MS DNA according to their 
alignments. If the observed bases of Indels are different than the bases of repeat 
unit, we called this as heterogeneous Indels. 
 
Figure 5.4 Selection of ESTs for analysis. ESTs covered entire MS DNA of 
reference sequences were selected and analyzed. Solid lines indicate qualified 
ESTs while dotted lines indicate EST that did aligned with entire of MS DNA. 
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5.3 Results 
5.3.1 Identification of putative Indels at coding microsatellite DNA 
 The alignment between ESTs and RefSeqs were generated by using 
BLASTN without repeat masking option in order to allow the alignments on MS. 
The aligned ESTs with the RefSeq were selected when the alignments met our 
standard (See 5.2.2). 6,078,016 alignments were selected for our analysis because 
they have clear single origin for the gene. Among these selected alignments, 
216,128 EST sequences aligned with MS DNA of genes were derived from mono 
MS DNA according to their coordination of alignments. Only Indels and 
substitution in the MS were considered while any other mutations outside of MS 
were not counted for this analysis. 6,459 coding MS DNA from 2,196 genes (48% 
of whole genes with coding MS DNA) were aligned with 10 or more supporting 
EST sequence. A total of 156,244 EST sequences were derived from MS DNA 
regions and 15,377 of them (9.8%) carried frame-shifted (FS) mutations. For the 
case of RNA-seq data, we used BLATN program to align qualified reads from 
three sets of RNA-seq data with their matched mRNA according to BWA 
alignments. The aligned reads with the RefSeq were selected when the alignments 
met our standard (See 5.2.2). The average number of coding MS DNA with 10 or 
more  10 supporting reads were 436.8 for breast cancer data, 395.9 for melanoma 
data, and 170 for prostate cancer data. 
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Table 5.2 Indel rate of coding MS DNA. The Indel rate = total bp of Indels / 
total bp of coding MS DNA in the alignments. 
Types Indel rate Insertion rate Deletion rate 
Breast 0.00376 0.00287 0.00089 
Melanoma 0.00426 0.00226 0.00201 
Prostate 0.00147 0.00118 0.00029 
EST 0.01331 0.00799 0.00541 
 
 Table 5.2 showed the estimated Indel rate from each data set. EST had the 
highest Indel rate while prostate data had the lowest Indel rate. Most of the Indels 
(about 97%) observed in RNA-seq data were homogenous Indels while about 
49% of Indels counted in EST data were heterogeneous indels. The observed 
insertions (9,593) outnumbered the observed deletions (5,762) in the EST data. 
However, homogeneous Indels had no significant difference between insertion 
and deletion. In most of RNA-seq data from breast and prostate samples, the 
number of insertion was significantly higher that the number of deletions for both 
homogenous and heterogeneous. Most of data from melanoma samples did not 
show any significant difference between insertion and deletion. The size of most 
Indels is 1 bp (> 90% in all data except deletion (86%) in EST data) In addition, a 
higher Indel rate was observed in longer microsatellites in general (Figure 5.5).  
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Figure 5.5 The Indel rate by repeat length. In general, a longer microsatellite 
has higher Indel rate. R2 values are 0.93, 0.61, 0.95, and 0.86 respectively for 
breast, EST, melanoma, and prostate. 
 In EST analysis, each tissue type showed different rate of Indels. Figure 
5.5 showed the Indel rate of 11 selected tissue types. The highest Indel rate was 
observed in bone marrow. Pancreas showed the biggest difference between tumor 
and normal libraries. Seven tissues types had significantly higher Indel rate in 
tumor than normal libraries (p<0.001); prostate, colon, pancreas, skin, brain, 
gastrointestinal tract, and stomach. Breast cancer may have a higher Indel 
occurrence in normal than tumor (significantly by p value = 0.1, but not by 0.05) 
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Figure 5.6 Indel rates by tissue types. Each tissue types has different mutation 
rate. Bone marrow, prostate and colon is in group of the highest mutation rate 
5.3.2 Characteristics of Insertion/deletion in coding MS DNA in tumor and 
normal  
 Based on the 2x2 contingency table, the occurrence of FS mutations 
collectively in tumor samples is significantly higher than normal samples (p < 
0.001, chi-square test) in EST data. Edgren et al. screened one normal breast 
sample and 6 breast cancer cell lines (60). The average number of 6 breast cell 
lines was used. The occurrence of FS mutations in normal breast was significantly 
higher than average of 6 cancer cell lines. In Kannan et al., there were matched 
tumor and normal samples from 10 patients (108). Only 2 out of 10 showed 
significantly higher rate in tumor than normal. 
Table 5.3 The comparison occurrence of frame-shifted mutations in coding 
microsatellite between tumor and normal. For EST data, we collectively count 
EST sequences for tumor and normal. The number of reads in tumor was counted 
from 6 breast cancer cell line and that in normal was counted from one normal 
breast sample. 10 pair of matched tumor and normal were used for comparison. 
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Highlighted ones had higher incidents of Indels in tumor than normal significantly 
(p<0.01, chi-square test); EST, breast, prostate #2, and prostate #23. 
Data Set 
Tumor Normal 
WT FS WT FS 
EST 60,123 7,461 82,984 6,504 
Breast 19,077 446 14,966 827 
Prostate #2 4,449 53 3,137 21 
Prostate #3 3,434 42 3,057 35 
Prostate #6 6,740 78 3,149 32 
Prostate #8 3,528 36 1,798 23 
Prostate #9 2,928 24 2,024 28 
Prostate #11 6,270 70 9,178 83 
Prostate #13 13,825 172 1,0574 100 
Prostate #15 14,736 139 8,282 63 
Prostate #19 14,304 136 7,404 88 
Prostate #23 12,511 151 9,243 73 
 
5.3.3 Putative candidates of coding microsatellite DNA  
 For EST data, we counted tumor and normal collectively since the overall 
coverage of microsatellite in one library was not high enough. 169 coding 
microsatellite with more than 5 supporting EST sequences for tumor and normal 
respectively had a significant difference in occurrence of Indels between tumor 
and normal. 142 of them had higher Indel rate of tumor than normal while 27 had 
an opposite trend. 88 frame-shifted peptides derived from Indels at 142 coding 
microsatellite will be longer than 6 amino acids. The top 10 candidates by chi-
square statistic were listed in Table 5.4. 
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Table 5.4 The list of top 10 coding microsatellite DNA. Among 88 coding MS 
DNA, this table shows the top 10 MS DNA that has more Indels in tumor than 
normal libraries according to chi square test. 
 
 
 We found six coding MS DNAs that showed an interesting distribution of 
Indels. When both insertion/deletion at a certain coding MS DNA were observed, 
most of them are 1 bp of insertion or deletion in general. However, these six MS 
DNA have a combination of either 1bp insertion and 2 bp deletion or 2 bp 
insertion or 1 bp deletion. As a result, they will have only one frame-shifted 
peptide instead of two possible ones (Table 5.5). 
Table 5.5 Biased distributions of Indels in terms of their size. Indels at these 6 
coding microsatellites had a skewed distribution of size of Indels considering that 
size of most Indels is 1bp. Highlighted one was generated by Indels among two 
possible frame-shifted peptides. Longer frame-shifted peptide was selected in the 
top three MS DNA while shorter frame-shifted peptide was selected in the bottom 
three MS DNA. 
 
WT FS WT FS
TM9SF2 282 A7 FS_del 8 29.67 110 14 253 0
PROL1 558 T7 FS_del 12 24.25 5 2 83 0
VCP 2228 A9 FS_ins 10 17.27 77 31 70 3
EIF3M 519 A7 FS_ins 8 15.65 169 31 197 8
BRD4 982 C7 FS_ins 44 14.75 4 10 13 0
CLDN6 621 G7 FS_ins 23 12.69 15 7 75 4
MFN2 753 T7 FS_del 10 11.79 23 3 149 1
ABR 2630 C7 FS_del 17 11.79 12 4 44 0
DGKZ 355 C7 FS_ins 84 10.47 6 4 23 0
SH3GLB2 1138 C7 FS_del 63 10.37 77 37 29 1
Chi sqaure
Tumor Normal
Gene Position MS DNA FS Len
GeneName Pos MS MS # Reads WT FS Ins List Ins Del List del FS-Del FS-Ins
ABCF1 313 A10 60 33 23 18 2,2,2,2,1,2,2,1,1,2,2,2,2,1,2,2,2,2 5 1,1,1,1,1 59 13
HELLS 2069 A7 36 17 11 4 1,1,1,1 7 1,2,2,2,2,1,1 14 24
C1orf144 241 A8 160 143 12 9 1,1,1,1,1,1,1,1,1 3 2,2,2 1 24
ATF4 1127 A7 88 65 14 6 1,1,1,1,1,1 8 2,2,2,1,2,1,1,1 35 9
ICA1 798 A9 7 2 5 1 1 4 2,2,2,2 4 1
SHCBP1L 1057 T7 6 0 5 0 5 2,2,2,2,1 83 1
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 We found 14 cases where there was only one microsatellite among 
multiple microsatellite from the coding region of a gene showed differential 
frame-shifted occurrence between tumor and normal (Figure 5.7).  
 
 
Figure 5.7 Different patterns between multiple microsatellites from a gene. 
TM9SF2 has 2 microsatellites in the coding sequence. A7 at position 282 has 
significantly frequent deletion in tumor than normal while A7 at position 560 has 
no significant difference. Red bar indicates tumor while blue bar indicates normal. 
 For three sets of RNA-seq data, we treated the data set independently 
since each run had high enough coverage unlike the EST data. 85 coding MS 
DNAs had significantly higher occurrence than the average at least one of seven 
breast samples. Some coding MS such as CCT5 had higher incident in 5 out of 7 
samples; BT474-1, BT474-2, MCF7, SKBR3-1,SKBR3-2.  144 coding MS DNA 
had significantly higher occurrence than expected at least one of melanoma 
cancer samples. 50 of them had higher incidents in multiple samples. In 30 
prostate cancer samples, 72 of the coding MS DNAs had significantly higher 
occurrence than expected at least one of prostate cancer samples. The occurrence 
of Indels at the 11 coding MS DNA was observed as above the average in all 
three sets (Table 5.6). We found 4 coding MS DNA that had differential FS 
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mutation rate between 10 matched tumor and normal from prostate samples 
(Table 5.7). 
Table 5.6 The list of coding MS DNA with high Indel rate. 11 coding MS 
DNAs showed high Indel rate in all three data sets relative to the average. There 
were total 40 tumor samples and 11 normal samples from three data sets. In the 
FS peptides, the first number is the size of a FS peptide from 1bp insertion and 
second number is the size of a FS peptide from 1 bp deletion. Bold indicates the 
observed a dominant Indel. 
Gene 
MS 
position MS 
# Tumor 
samples 
# Normal 
samples FS peptides 
RPL22 83 A8 22 9 8  / 4 
VCP 2228 A9 20 3 10 / 62 
P4HB 1350 A8 18 8 21 / 117 
CCT5 891 A7 12 0 13 / 25 
VEGFB 419 A8 9 1 34 / 4 
TMBIM4 587 T10 9 0 2 / 15 
PSMA6 648 A8 8 0 5 / 0 
SEC62 452 A9 7 1 8 / 63 
HNRNPH1 1038 T8 6 1 0 / 39 
TCF25 467 A9 4 1 26 / 16 
SF3B2 2658 A8 4 1 15 / 21 
 
Table 5.7 The comparison of the occurrence of Indels at coding MS DNAs 
between matched tumor and normal. Among the coding MS DNAs with 10 or 
more supporting reads in both tumor and normal, 4 coding MS DNAs showed 
differential incidents of Indels between tumor and normal. 2 of them were 
frequent in tumor while 2 of them were frequent in normal. 
Samples Gene 
MS 
position 
MS 
Tumor Normal 
WT FS WT FS 
C03 / N03 RPL22 83 A8 32 5 36 0 
C08 / N08 RPL22 83 A8 64 5 25 7 
C23 / N23 MIF 197 C7 180 3 414 0 
C23 / N23 OR51E2 704 T8 115 1 16 3 
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5.4 Methods & Materials 
5.4.1 Collection of sequences  
Human Reference mRNA sequences were downloaded from NCBI (August 2011 
version). This data set contains 32,871 mRNA from 19,763 genes. About 8 
million EST sequences were also downloaded from NCBI (December 2010 
version). Three sets of RNA-seq data were obtained from Sequence Read Archive 
(SRA), NCBI. The first set had 7 runs from 6 breast cancer cell lines and one 
breast normal sample (60). In the second set, there were 14 runs from melanoma 
patient and cell lines (58). The third set contained 30 runs from 10 matched 
prostate tumor and normal samples and 10 prostate tumor patients (108). 
5.4.2 Selection of qualified sequences  
 First, all EST sequences were aligned with human mRNA Reference 
Sequences by BLASTN program. EST sequences that aligned with a single 
reference sequence or single loci were selected based on similarity and length of 
alignments and their origin. The similarity and length of alignments has to be ≥50 
bp with 97% similarity, ≥85 bp with 95% similarity or ≥100bp with 90% 
similarity. In addition, they have to be located unambiguously in single reference 
sequence or loci.  The origin of the EST was unequivocal when there was only 
one alignment with a reference sequences or the blast score of the best alignment 
was higher than that of second best alignment by at least 50. We excluded non-
coding RNA from second best alignment with the only exception when they had 
the exact same blast score with the best one. After all applied criteria, we selected 
EST sequences that had the best alignments only from a single gene. The longest 
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mRNA was selected for further analysis when there were multiple isoforms for a 
gene. 
 All reads from RNA-seq data were aligned against human mRNA 
Reference Sequences by using BWA program version (109). The reads that had 
mapping quality score is 30 or higher and aligned with coding MS DNA were 
selected. These reads were aligned again with matched human RNA by using 
BLASTN.  
5.4.3 Selection of coding MS DNA with higher rate of Indels 
  The average occurrence of frame-shifted mutations from all runs in a set 
was calculated at first. Simply, we counted all Indels collectively in each study. 
Afterward, we identified the coding microsatellite DNAs with higher occurrence 
in each sample by comparing with the average of Indel. The chi-square test was 
used to assess statistically significance. 
5.5 Discussion 
 The question addressed by this study was whether Indels at coding MS 
DNA are a good source of antigens for a cancer vaccine. Due to their high 
mutation rate, we may expect to observe frequent Indels at MS DNA in tumor 
samples. Therefore, we are interested in identifying what coding MS DNAs have 
frequently Indels in many tumor samples, but not in normal samples. Our analysis 
showed that some of coding MS DNA have higher Indel rate in multiple tumor 
samples, but not or few in normal samples (Table 5.4 and Table 5.6). These 
coding MS DNA could generate frame-shifted peptides that could be used as 
antigens for a cancer vaccine. 
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  I presume the chance of having a sequencing error will be same in tumor 
and normal samples. Therefore, we can tell that Indels at a coding MS DNA more 
frequent occurred in tumor than normal when more Indels were observed in 
transcriptome data from tumor samples comparing to normal samples. Since we 
required the minimum number (6 for EST and 10 for RNA-Seq) of supporting 
reads respectively from tumor and normal in order to do chi-square test, we may 
miss some good candidates of coding MS DNA that had no supporting reads from 
normal samples. 
 I expect that more Indels at coding MS DNAs will be observed in tumor 
when these Indels are associated with cancer. Therefore, the coding MS DNA in 
Table5.6 might be a good candidate since the biased distribution of Indels might 
indicate their association with cancer development. I speculate that this might be 
oncogenic function because either insertion or deletion can truncate the protein, so 
there is no necessity for one dominant way of doing it. However, 3 out of 6 
produced a short peptide instead of long one. It is hard to say that 1 amino acid 
confer a new function. 
 In summary, this study has shown the potential use of coding MS DNA as 
vaccine antigens by analyzing transcriptome data and antibody reactions. The 
pipeline of analyzing transcriptome for coding MS DNA should be easier and 
more accurate when we have more data generated by next-generation sequencing 
technology. Therefore, the systematic analysis shown in this study may provide 
more reliable coding MS DNA that could be tested in animal model when more 
sequencing data are available. 
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5.6 Conclusion 
 Coding MS DNAs may be a good source of FS antigens considering their 
high Indel rate and functionality in the context of cancer. Furthermore, the genetic 
instability of cancer elicits more mutations in MS DNAs. Their mutation rate is 
the highest among spontaneous mutations. The analysis of EST and RNA-seq in 
this study supports the feasibility of this idea. The low coverage of coding MS 
DNA in the current transcriptome will be improved by targeted sequencing. 
Therefore, we can select better coding MS DNA for antigen candidates. 
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CHAPTER 6  
FRAMESHIFTED ALTERNATIVE SPLICING VARIANTS 
6.1 Introduction 
 Alternative splicing, a well-studied event in eukaryotes, increases the 
diversity of proteins with critical roles in regulation of cells. In fact, alternative 
splicing is a highly controlled procedure and a critical process that produces 
significant impact in the regulatory and developmental biology of organisms 
(110). In humans, 92~94% of total genes have multiple isoforms generated by 
alternative splicing, and a large number of them are tissue-specific variants (48). 
As anticipated, abnormal splicing variants derived from mis-regulation in splicing 
mechanisms are also implicated in cancer. While tumor suppressors are often 
inactivated by splicing in cancer cells, oncogenes are often activated by this 
process (111). In fact, several studies reported tumor-specific alternative splicing 
that had not been detected in normal tissues (112-114). 
 Abnormal splicing variants in cancer have been tested as a potential 
source of biomarkers, diagnostic, prognostic, and therapeutic targets for cancer. 
Many studies have shown splicing variants are either tumor-specific or tumor-
associated.  For instance, alternatively spliced NF1 in neurofibroma (115), 
variable CD44 in breast cancer (116), truncated DNMT3B in non-small cell lung 
cancer (117), aberrant KLF6 in prostate, colon, and lung cancers (118-120), and 
isoform Ron in breast and colon (121) have been shown to be associated with 
tumors. As for biomarkers, 41 splicing variants were listed as potential markers 
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for breast cancer by Venables et al.(50), and 48 alternative iso-forms were 
suggested markers for ovarian cancer by Klinck et al.(49). In addition, several 
splicing variants have been used as prognostic indicators: RHAMM and HAS1 for 
multiplemyeoloma (122, 123), survivin2B for metastatic gastric, breast and 
colorectal cancers (124-126), and CD44v6 for prostate cancer (127). 
 Frame-shifted splicing variants, which generate frame-shifted peptides out 
of new exon combinations, have not been studied extensively. We speculated that 
frame-shifted alternative splicing may contribute to cancer development since 
frame-shifted mutations affect protein sequences dramatically. Truncated proteins 
by frame-shifted splicing may result in loss of functional domain, which could 
inactivate the pathways of tumor suppressors. These frame-shifted peptides could 
be good cancer antigens if they occur frequently in cancer samples. To test the 
feasibility of this idea, we did a bioinformatics analysis on the transcriptome data 
to get the frequency of each identified frame-shifted splicing variant.  Translated 
peptides and potential epitopes were then able to be accurately predicted. The 
bioinformatics analysis in this study provided us a list of putative frame-shifted 
splicing variants as candidates for cancer antigens. It is anticipated that the vast 
amount of transcriptome data of various cancers from next-generation sequencing 
will enhance our ability to further select better cancer antigen candidates derived 
from splicing variants. 
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6.2 Bioinformatic Approach 
6.2.1 Data Sets 
 To identify potential putative neo splicing variants, that when translated 
would result in a frame-shifted neo-peptide, two publically available datasets 
were applied in an algorithm that was used to identify splicing variants. 
Specifically, we used the sequences found within the Expressed Sequence Taq 
(EST) library (51) and the Human RefSeq database (76) from the National Center 
for Biotechnology Information (NCBI). 
6.2.2 Algorithm 
Using the stand-alone BLAST program, we aligned all EST sequences to 
RefSeq. We selected the alignments of EST sequences with RefSeq when they 
have met one of following conditions: ≥50 bp of length with 97% or more of 
sequence similarity, ≥85 bp of l ength with 95% or higher sequence similarity, or 
≥100 bp of length with 90% or higher sequence similarity. There were some ESTs 
that had more than one qualified alignment that were derived from different 
regions of the EST. Due to local alignment by BLAST, splicing variants will 
generate separate alignments. As a default setting of BLAST, top alignments will 
be the best alignments by BLAST score. Any qualified alignments outside of the 
top alignments by at least 50 bp were identified. Based on this, we were able to 
count the number of distinctive regions that were aligned in an EST sequence. 
 To simplify the analysis, we analyzed only ESTs that had two matching 
alignments from a single RefSeq, instead of analyzing ones with three or more 
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alignments. Only ESTs of which had all qualified alignments from a single 
RefSeq were considered to be potential candidates. When both aligned regions in 
an EST each has multiple matching alignments with different RefSeqs, the 
common matching RefSeq in both regions was selected. If there were more than 
one common RefSeqs, the more frequently matched one was selected. There are 
four combinations of splicing variants in terms of the direction of two alignments; 
++, + ─, ─ +, and ─ ─. The subject sequence, or the RefSeq, can be aligned from 
5’ to 3’ (+) or from 3’ to 5’ (─), relative to the query sequence, or the EST.  For 
the cases of ─ ─, their orientations were reversed to ++. In addition, ─ + EST 
sequences were excluded from further analysis because the leading reverse 
strands of RefSeqs could not be properly translated into peptides. Furthermore, 
only NCBI accession numbers that begin with the prefix NM_ were used due to 
their precise exon boundaries. Finally, any nucleotides that fall within both 
matched alignments in an EST were not counted more than once. The position of 
the downstream alignment in the EST sequence, along with its corresponding 
position in the Refseq, was shifted by the size of the overlapped region 
accordingly. To eliminate false calls, all identified novel splicing variants had to 
be supported by EST sequences from more than one cDNA library. Additionally, 
novel splicing variants that occurred at exon boundaries were counted even 
though all supported EST sequences were from only one library.  
The adjusted alignments of an EST sequence with a RefSeq showed four 
different types of splicing variants; exon inversion, exon skipping, intron retention 
and a combination of exon skipping and intron retention (Figure 6.1). We only 
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considered exon skipping, because the entire configuration of exons or the exact 
sequences of transcripts for the other three cases could not be computed based on 
current data. For exon skipping, we used EST sequences only for identifying exon 
junctions. Sequences of splicing transcripts were then determined by using 
RefSeq in order to predict peptide translation. 
 
Figure 6.1 Types of splicing variants by aligned positions. Four positions (B, 
C, F, and G) were used to determine the types of splicing variants. 
 Among selected splicing variants, we identified those that were a result 
from frame-shifted mutation. Splicing variants without either a start codon or in-
frame splicing variants were excluded. Furthermore, we also excluded frame-
shifted splicing variants with neo-peptides consisting of less than 8 amino acids. 
Finally, we examined whether they were tumor-associated or not by counting the 
number of tumor and normal libraries in which matching ESTs were detected. 
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Splicing variants were regarded as tumor-associated only when they meet the 
following conditions: i) not present in normal libraries, and present in at least 3 
Tumor libraries; ii) the occurrence in tumor libraries is at least 3 times higher than 
that in normal libraries. 
6.3 Results 
6.3.1 Identification of novel alternative splicing  
 We used our semi-automatic alignment algorithm to identify frame-shifted 
alternative splicing variants from the available NCBI EST sequence database 
(Figure 6.2). Briefly, to support a splicing variant, one EST sequence must have 
two alignments with a RefSeqs. Considering the EST database contains 
approximately 8M EST sequences, we outlined filtering criteria that was applied 
to eliminate irrelevant sequences. Among qualified ESTs, 193,849 EST sequences 
had multiples alignments at distinctive positions with a RefSeq. To simply 
analysis, 216,218 EST sequences that had two aligned regions were selected for 
further analysis. In addition, we discarded the EST sequences that did not align 
properly with well annotated RefSeqs with accession number that begin with the 
prefix NM_. After removing 4,179 EST sequences with 3’ to 5’ of upstream 
RefSeq and 5’ to 3’ of downstream RefSeq, we identified 19,121 novel splicing 
variants supported by these EST sequences. 
 Novel splicing variants were classified into four types based on positions 
of two alignments. First, 389 variants had inversed order of exons. Second, 
12,456 variants skipped some exons. Third, 6,726 gained addition sequences from 
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intron with/without exon skipping. To have precisely predicted peptides, only 
12,456 exon skipping variants were considered. By our criteria, putative novel 
splicing variants had to meet two conditions; supporting EST sequences from 
more than one library or exon-exon combination in one library. Finally, 9,088 
variants were supported by EST sequences from two or more libraries. 571 
variants occurred at the exact exon boundaries in one library. A total of 9,659 
qualified variants were identified as exon skipping variants. 
 
Figure 6.2 Identification of novel splicing variants. 
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6.3.2 Putative tumor-associated splicing frame-shifted variants 
 Figure 6.3 shows the brief scheme to identify tumor-associated frame-
shifted splicing variants. Among 9,659 putative novel splicing variants, frame-
shifted peptides will be translated from 4,506 variants. 2,996 of them will have 
frame-shifted peptides with 8 or longer amino acids. According to our criteria, 
total 96 tumor-associated frame-shifted variants were identified (Table 6.1). The 
average length of frame-shifted peptide is 29.4 amino acids with the range of 8 
amino acids to 167 amino acids. 34 of them had exon-exon combination while 
new junction of remaining 62 variants occurred in the middle of known exons.  
 
 
Figure 6.3 Identification of tumor-associated frame-shift splicing variants. 
Among selected 9,659 splicing variants as qualified ones, 4,506 (46.7%) could 
generate frame-shift peptides. We only considered the 2,996 splicing variants with 
8 or longer amino acids for higher chance of having possible epitopes. 96 splicing 
were regarded as cancer-associated ones. 
Table 6.1 Putative tumor-associated splicing variants. This table shows 20 out 
of 96 candidates including two cancer genes (indicated by *) by Sanger Inst. 
RefSeq_ID is NCBI accession number. FS length means the length of frame-
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shifted peptides from splicing variants. #Tumor_lib and #Normal_lib indicates the 
number of libraries to support each splicing variants. 
 
6.3.3 Experimental validation 
 To validate the presence of these predicted splicing variants, we screened 
several cancer cell lines by RT-PCR. We amplified both wild type and alternative 
splicing products by using primers we designed (Figure 6.3). RNA samples from 
5 different cancer cell lines were used; panc1 (pancreatic cancer), brain  (brain 
cancer), A-459 (lung cancer), SW-480 (colon cancer), and MCF7 (breast cancer).  
The expected size of band was confirmed by sequencing.  Protein phosphatase 4, 
catalytic subunit (PPP4C) had very faint splicing variants in all cancer types. 
Expected splicing variant of member RAS oncogene family (RAB34) were 
detected in pancreatic, breast, and lung cancer cell lines, but not in colon and 
breast cancer cell lines. Prune homolog (Drosophila)  (PRUNE) and mitogen-
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activated protein kinase kinase kinase 10 (MAP3K10) were amplified the product 
of splicing variant in all cancer types that we examined.  
 
Figure 6.4 Experimental validation using RT-PCR. P, B, L, C, BR denote 
pancreatic tumor, brain tumor, lung tumor, colon tumor, breast tumor 
respectively. Wild type and frame-shifted products are indicated. A. PPP4C; 207 
bp for wild type, 154 bp for alternative splicing. B. RAB34; 463 bp of wild type, 
371 bp for splicing variant. C. PRUNE; 374 bp for wild type, 171 bp for 
alternative splicing. D. MAP3K10; 412 bp for wild type, 216 bp for splicing 
variants. 
6.3.4 The example case; SMC1 
 These data were generated by Luhui Shen. SMC1 was one of our putative 
candidates, which resulted in producing 17 amino acids of neo-peptide. In fact, 
  90 
our team had preliminary results based on this SMC1. The frame-shifted variants 
were detected in both tumor and normal samples with differential expression. 
However, the tumor growth was clearly delayed in the mice vaccinated with the 
FS vaccine relative to controls (data not shown). 
 
 
Figure 6.5 The frame-shifted splicing variants of SMC1. a. RT-PCR screening 
of SMC1 transcripts in primary breast tumor samples. b. The relative expression 
level of splicing variants. Luhui Shen provided figures. 
6.4 Methods 
6.4.1 Computational analysis  
Refer to section 6.2. 
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6.4.2 Experimental Validation  
 Primers were designed by a program, called “Primer3” (87) to amplify 
both wild type and splicing variants. The sequences of primer pairs were shown in 
Table 6.2. 
Table 6.2 The sequences of primer pairs for RT-PCR. FW, Rev, WT, and AS 
denote forward primer, reverse primer, product size of wild type, and product size 
of alternative splicing respectively. 
 
 Total RNA was extracted from cancer cell lines using the TRIzol LS 
reagent (Life Technologies, Carlsbad, CA) following the manufacturers protocol. 
cDNA was prepared by using the SuperScriptTM III First-Strand Synthesis 
SuperMix (Life Technologies, Carlsbad, CA) that includes random hexamers and 
oligo dT’s following the  manufacturer’s recommended protocol. cDNA integrity 
and quality were assessed by performing a β-actin control PCR. PCR reactions 
were carried out using approximately 25 ng of cDNA, reagents from (Life 
Technologies, Carlsbad, CA) and 35 cycles were performed using Mastercycler 
ep gradient S (Eppendorf, Hamburg, Germany). Amplification conditions were as 
follows; 95°C for 2 min; 35 cycles of 95°C for 30 sec, 55°C for 20 sec, 72°C for 
20 sec. PCR products were analyzed on 1.5% agarose gels. PCR products were 
purified and sequence confirmed by Applied Biosystems 3730 (Life 
Technologies, Carlsbad, CA). 
Gene FW Rev WT AS
RAB34 GCGGTGGTCGTAGCGTCTC CAGCACCTCAAATCGTTCCATC 463 371
PPP4C TCATCAAGGAGAGCGAAGTC AGCCACGGTCCACAAAGTC 207 154
PRUNE GAAGCCTGTGATTTGGACTC AGCACAGGACCCCACCAG 374 171
MAP3K10 CACAAGACCACCAAGATGAGC TGGTCCGAAGGTCATCAAAC 412 216
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6.5 Discussion 
 The question addressed by this study was whether frame-shifted splicing 
variants are a good source of antigens for a cancer vaccine. In this study, we 
identified frame-shifted splicing variants and validated them in cancer cell lines 
by RT-PCR. Some of frame-shifted transcripts may not be subject to non-sense 
mediated decay (NMD) as observed in this study, and then may be translated into 
peptides. At least, the evidence at the mRNA level supports the potential use of 
frame-shifted splicing variants as vaccine antigens. In fact, frame-shifted splicing  
In fact, several frame-shifted splicing variants were identified as cancer specific 
marker. 9 frame-shifted splicing variants significantly differed in breast tumors 
compared to normal breast tissues (50). In addition, we may not identify 
alternative first exon (AFE) and alternative last exon (ALE) since we aligned EST 
sequences with mRNA that could not provide the information about a neo 
first/last exon. In addition, several studies reported truncated proteins by splicing 
in cancers; A-Raf, VEGFR, BCR-ABL, JAK2, and TrkB (128). 
 Eight different alternative splicing events were suggested by Wang et al 
(48). However, we used only exon-skipping to simplify the analysis. Splicing 
events generated from non-coding regions such as 5’ UTR or 3’ UTR were 
ignored in this study because we are interested in frame-shifted alternative 
splicing, which had to occur within an exon. 
 The function of these truncated proteins has not been clearly understood. 
However, for vaccine development, we are more interested in their frequency and 
immunogenicity. We examined the presence of these frame-shifted splicing 
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variants in normal samples. In fact, most of these splicing variants were detected 
in normal samples even though the expression level was significantly different 
between tumor and normal sample. However, this difference in the amount of 
transcripts may make a difference at the protein level. As a proof of principle, the 
FS SMC1 that is detected in both tumor and normal tissues showed the delay of 
tumor growth in mouse model (data not shown) according to our immunology 
team. Therefore, tumor-specificity of splicing variants could not be determined 
precisely at the transcript level. 
 We can expect that RNA-seq data generated by next-generation 
sequencing technology enable us to identify more slicing variants with higher 
accuracy. Sequencing biased toward 5’ or 3’ end in EST sequences will be 
diminished in RNA-seq data. More splicing variants involved with middle exons 
will be identified. The systematic bioinformatics approach suggested in this study 
will guide us to extract the useful information about frame-shifted splicing 
variants. 
6.6 Conclusion 
 It is worth testing the potential of frame-shifted splicing variants as cancer 
vaccine antigens. Our studies showed that about half of aberrant splicing in cancer 
samples was frame-shifted, which is consistent to the result from Venables et al. 
(50) for their maker for breast cancer. Some of them were detected in multiple 
samples. However, all the frame-shift splicing variants that we tested were found 
in normal samples as well. The difference in expression level of transcripts may 
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result in the presence of frame-shifted peptides in tumor, but not in normal. 
Therefore, we need to have follow-up immunological experiments to validate our 
candidates. However, our approach can provide the list of probable candidates 
that could work as antigens by using the information embedded in transcripts. 
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CHAPTER 7  
CONCLUSION 
 We started by asking whether frame-shifted mutations, if any, can be used 
as antigens for a prophylactic cancer vaccine because, in general, these neo-
peptides from frame-shifted mutations yield more epitopes compared to one new 
amino acid from point mutations in general. And then we asked what kind of 
frame-shifted mutations could qualify as suitable antigens. Each chapter in this 
dissertation explored the possibility of different mutation types that resulted in 
frame-shifted mutations through the use of cancer transcriptome. The Expressed 
sequence tag (EST) sequences deposited into National Center for Biotechnology 
and Information (NCBI) and sequences of transcripts generated from next-
generation sequencing technology enables us to retrieve the information about 
frame-shifted mutations in cancer as well as normal samples. Their frequencies, 
tumor-specificity, and number of possible epitopes were also obtained by our 
bioinformatic approach. The potential use of frame-shifted mutations as cancer 
vaccine antigens was mainly evaluated by means of this acquired data. Amongst 
the vast extent of all possible frame-shifted peptides derived from coding 
sequences in the human genome, this evaluation may guide us in narrowing down 
the possibilities to a specific list of frame-shifted mutations,  the targeted probable 
potential candidates, to be tested in animal models for immunogenicity.  
 This study has shown that frame-shifted mutations have a high chance of 
being appropriate antigens for prophylactic cancer vaccine at the mRNA level. 
Considering the cost of evaluating antigens in animal models, the proposed 
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pipeline of analysis using transcriptome data in this study readily provides a list of 
highly probable candidates to be tested in animal models. 
 Since all candidates were deduced from the mRNA level, follow-up 
experiments are required. These candidates may, on the other hand, even deem to 
be unsuitable candidates. Nevertheless, it is worth pursuing the possibility as to 
whether frame-shifted mutation may be used as vaccine antigens. Therefore, the 
candidates are ranked on our ranking system. The cancer transcriptome data will 
enable us to achieve more accurate ranking in the future. Furthermore, any 
research group can implement this list with the ranking system to select the best 
candidates for their follow-up experiments. 
7.1 Ranking system 
 Essentially, we use the population coverage of each antigen as the primary 
contributing score for the ranking. The population coverage of an antigens is 
determined by two factors; the frequency of mutation and coverage of possible 
epitopes. Additionally, we provide two more pieces of information along with 
ranks; normal samples and homologous genes in animal models such as mice and 
dogs. In fact, the presence of antigens in normal samples is very critical 
information for vaccine antigens as well as other applications such as diagnostics 
and drug targets. However, we cannot decide their presence as peptides (antigens) 
in normal samples by using only transcriptome data. From our studies, most of 
aberrant transcripts in cancer samples were also found in normal samples even 
though their expression level was low. It is difficult to resolve whether these low-
level transcripts will be translated into peptides or not. Therefore, this 
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determination is left for further experimentation. The information about 
homologous genes will be useful for researchers who are working on animal 
models. Finally, we are able to make a ranking table for all the candidates from 
viral sequences, chimeric transcripts, coding MS DNA, and splicing variants 
(Table 7.1). 
Table 7.1 The ranking table. The score of each FS mutation will be calculated as 
follows; h = f * g where f indicates total frequency of mutation and g indicates the 
epitope coverage. First the total frequency of mutations (f) will be calculated 
based on the prevalence of each cancer type. The frequency of each cancer type 
was obtained from “Cancer Statistics 2011” (1).  The formula for calculating the 
total frequency therefore is the sum of the frequency of each cancer type 
multiplied by the frequency of mutations in that cancer type (a, b, c, d, e): f = 
0.14*a + 0.15*b + 0.14*c + 0.03*d + 0.09*e where a, b, c, d, and e refer to breast, 
prostate, lung, pancreas, and colon cancer types respectively. The frequency of 
mutation in each tissue type can be determined from transcriptome data by our 
bioinformatics approach. Second, epitope coverage (g) will be determined by 
using the algorithm from the Immune Epitope Database and Analysis Resource 
(IEDB).  The rank of each mutation is determined by this score (f). Additional 
information will be included in the table which does not use a calculated score. 
The normal column of this additional data indicates whether mutations were 
detected in normal samples. The columns “Mouse” and “Dog” refer to the 
presence of homologous genes in each species respectively. Antibody reactivity 
against predicted peptides may be provided by an immunosignaturing. 
 
7.2 Future directions 
 First, the vast amount of transcriptome data from tumor and normal 
samples will help us to attain greater accuracy of the frequency of aberrant 
transcripts in cancer as well as normal samples. Currently, a deficit in screening 
of normal samples hinders us to predict their presence in normal samples. These 
current limitations will be lifted by the vast amount of data from various tissue 
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types and normal samples in the near future. Second, immunosignauring 
technology, which is under development at CIM at the Biodesign Institute, can 
provide us information regarding whether each antigen is reactive with antibodies 
from samples of normal and tumor samples. We expect that our ranking table 
approach will maximize the use of cancer transcriptome data to obtain a relevant 
list of neo tumor antigens for development of cancer vaccine. 
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Table A.1 The list of viruses without vec-screening 
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Table A.2 The list of 48 viral peptides on the chip. These peptides were 
predicted B cell epitopes from viral proteins. ‘Origin’ column indicates which 
virus and proteins the peptides derived from 
Peptide Origin 
PKKPRGPRGPRP 
Murine type C retrovirus( hypothetical protein 
MtCrVgp1 ),Xenotropic MuLV-related virus VP62( 
putative gag-pro-pol polyprotein , putative gag 
polyprotein ),Rauscher murine leukemia virus( gag 
polyprotein ),Friend murine leukemia virus( gag 
protein ),Spleen focus-forming virus( gag polyprotein 
fragment ),Moloney murine leukemia virus( Pr180 , 
Pr65 ) 
PYDPEDPGQE 
Murine type C retrovirus( hypothetical protein 
MtCrVgp1 ),Xenotropic MuLV-related virus VP62( 
putative gag-pro-pol polyprotein , putative gag 
polyprotein ),Moloney murine sarcoma virus( Pr65 
),Rauscher murine leukemia virus( gag polyprotein 
),Friend murine leukemia virus( gag protein ),Moloney 
murine leukemia virus( Pr180 , Pr65 ) 
DNHSGESNKETSD 
Rachiplusia ou MNPV( DNA helicase ),Plutella 
xylostella multiple nucleopolyhedrovirus( DNA 
helicase ),Bombyx mori NPV( DNA Helicase 
),Bombyx mandarina nucleopolyhedrovirus( DNA 
helicase ),Autographa californica 
nucleopolyhedrovirus( helicase ) 
APDNDDPNFE 
Rachiplusia ou MNPV( global transactivator ),Plutella 
xylostella multiple nucleopolyhedrovirus( global 
transactivator ),Bombyx mori NPV( GTA ),Bombyx 
mandarina nucleopolyhedrovirus( GTA ),Autographa 
californica nucleopolyhedrovirus( global transactivator-
like protein ) 
SGRGGMPSTTRGSNDGE 
Human herpesvirus 4 type 2( BPLF1 ),Human 
herpesvirus 4( BPLF1 ) 
RPGGPEEGAVPGPGRPEA
E 
Human herpesvirus 4 type 2( BALF3 ),Human 
herpesvirus 4( BALF3 ) 
GTRPDLTDQPIPD 
Xenotropic MuLV-related virus VP62( putative gag-
pro-pol polyprotein ) 
KSKPPKPQVLPD Xenotropic MuLV-related virus VP62( putative gag-
pro-pol polyprotein , putative gag polyprotein ) 
QTNQAGGEAPQPGDNST Human herpesvirus 4( BZLF1 ) 
EPDSRDQQSRGQRRGD Human herpesvirus 4 type 2( EBNA-3C ) 
ASGMGTPATAEPAPPSN Abelson murine leukemia virus( p120 Gag-Abl 
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polyprotein ) 
DEDNQDDDDATTSYGKP Beilong virus( nucleocapsid protein ) 
TKEEGATKKKTQKP Bovine viral diarrhea virus 1( polyprotein ) 
SLDQGEPTNPSDAAAK Canine parvovirus( polyprotein ) 
SPRRRTPSPRRRRSQ Hepatitis B virus( precore/core protein , Core and e 
antigen ) 
TSPSPPVEQPQVGQ Human adenovirus C( control protein E4orf6/7 ) 
RPPGPPSGPSPDASPEA 
Human herpesvirus 1( DNA replication origin-binding 
helicase ) 
RQRSQPGSAQGSGKRPP 
Human herpesvirus 5( DNA polymerase catalytic 
subunit ) 
PSTNKPTNSQAKSSTKP Human herpesvirus 8( KCP ) 
IGPRKRSAPSATTSSK Human papillomavirus - 18( L1 protein ) 
ETETPCSQYSGGSGGGC Human papillomavirus type 16( E1 ) 
GQKNNNPSFSED Murine osteosarcoma virus( gag polyprotein ) 
SVGGGAKPKKPR Parainfluenza virus 5( phosphoprotein , V protein ) 
KESEKDSRTKPP Pestivirus Giraffe-1( polyprotein ) 
RKGSCPGAAPKKPKEPV Simian virus 40( Major capsid protein VP1 ) 
PKKIQPPTQLPTQPNAP Squirrel monkey retrovirus( gag protein ) 
TEEERQEREKKEAEE 
Woolly monkey sarcoma virus( pre-gag ORF protein , 
hypothetical Gag polyprotein ) 
QAPEDQGPQREPH Human immunodeficiency virus 1( Vpr , Vpr ) 
EPQLRDETTPNDDAD Enterobacteria phage ID18 sensu lato( gpB ) 
HPKPPPPLPPSAPSL 
Abelson murine leukemia virus( p120 Gag-Abl 
polyprotein ) 
QKQPGAVGGPVKKGA Beilong virus( W protein ) 
SEKDSKTKPPD Bovine viral diarrhea virus 1( polyprotein ) 
AVQPDGGQPAV Canine parvovirus( polyprotein ) 
GSSSGTVNPVPTTAS Hepatitis B virus( large S protein , middle S protein ) 
KKRPSPKPERPPSP 
Human adenovirus C( single-stranded DNA-binding 
protein ) 
VPPQGAEPQSNAGPRPH Human herpesvirus 1( thymidine kinase ) 
TSPDDSSSGEVPDHPTA Human herpesvirus 5( membrane glycoprotein UL18 ) 
TGAESEDSGDEGPSTRH Human herpesvirus 8( vIRF-3 ) 
ADPEGTDGEGT Human papillomavirus - 18( E1 protein ) 
AISDDENENDSDTG Human papillomavirus type 16( E1 ) 
DPEPKPSLE Murine osteosarcoma virus( gag polyprotein ) 
TQQVPRPGTGDC Parainfluenza virus 5( hemagglutinin-neuraminidase 
protein ) 
LTEGPPPKE Pestivirus Giraffe-1( polyprotein ) 
FNPEEAEET Simian virus 40( large T antigen ) 
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PIPPANPCPPSNQP Squirrel monkey retrovirus( protease ) 
SPGTSQEQRA Woolly monkey sarcoma virus( Env protein , p28sis ) 
STEGSNNTEGS Human immunodeficiency virus 1( Nef , Nef ) 
QGSNPPNGQQAA Enterobacteria phage ID18 sensu lato( gpH ) 
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Table B.1 The sequences of primers for screening of chimeric transcripts in 
human 
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Table B.2 The sequences of primers for screening gene fusions in mouse 
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Table B.3 The sequences of primers for screening gene fusions in dog 
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Table B.4 The 50 human breast cancer cell lines. 
No. Cell Line ATCC_Name Tissue 
1 MCF-10A CRL-10317 breast 
2 BT-474 HTB-20 breast 
3 Hs 319.T CRL-7236 breast 
4 HCC1428 CRL-2327 breast 
5 HCC1599 CRL-2331 breast 
6 Hs 605.T CRL-7365 breast 
7 Hs 362.T CRL-7253 breast 
8 ZR-75-1 CRL-1500 breast 
9 MCF-7 HTB-22 breast 
10 Hs 281.T CRL-7227 breast 
11 HCC1500 CRL-2329 breast 
12 BT-20 HTB-19 breast 
13 HCC1143 CRL-2321 breast 
14 UACC-812 CRL-1897 breast 
15 SW527 CRL-7940 breast 
16 MDA-MB-453 HTB-131 breast 
17 ZR-75-30 CRL-1504 breast 
18 MDA-MB-468 HTB-132 breast 
19 HCC1187 CRL-2322 breast 
20 SK-BR-3 HTB-30 breast 
21 MDA-MB-175-VII HTB-25 breast 
22 Hs 574.T CRL-7345 breast 
23 HCC 1008 CRL-2320 breast 
24 Hs 742.T CRL-7482 breast 
25 Hs 748.T CRL-7486 breast 
26 BT-483 HTB-121 breast 
27 HCC202 CRL-2316 breast 
28 HCC 2157 CRL-2340 breast 
29 BT-549 HTB-122 breast 
30 MDA-MB-415 HTB-128 breast 
31 HCC1395 CRL-2324 breast 
32 
 
HTB-127 breast 
33 MDA-MB-231 HTB-26 breast 
34 CAMA-1 HTB-21 breast 
35 MDA-MB-134-VI HTB-23 breast 
36 Hs 606.T CRL-7368 breast 
37 HCC1806 CRL-2335 breast 
38 HCC1419 CRL-2326 breast 
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39 AU565 CRL-2351 breast 
40 HCC1937 CRL-2336 breast 
41 Hs 578T HTB-126 breast 
42 Hs 739.T CRL-7477 breast 
43 DU4475 HTB-123 breast 
44 HCC70 CRL-2315 breast 
45 HCC38 CRL-2314 breast 
46 HCC1954 CRL-2338 breast 
47 MB 157 CRL-7721 breast 
48 HCC2218 CRL-2343 breast 
49 Hs 343.T CRL-7245 breast 
50 UACC-893 CRL-1902 breast 
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Table B.5 Dog samples for screening 
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Table C.1 The list of gene fusions used in pattern analysis 
 
 
5' Gene 3' Gene 5' Gene 3' Gene 5' Gene 3' Gene 5' Gene 3' Gene
SEPT8 AFF4 DEDD NIT1 HMGA1 LAMA4 ITPR2 ETV6
ABHD14A ACY1 DEK NUP214 HMGA2 CCNB1IP1 JAZF1 PHF1
AC141586 CCNF DEPDC1B ELOVL7 HMGA2 COX6C JAZF1 SUZ12
ACAD10 ALDH2 DLEU2 PSPC1 HMGA2 CXCR7 KCNQ5 RIMS1
ACBD6 RRP15 DMRT1 BCL6 HMGA2 EBF1 KCTD2 ARHGEF12
ACSF2 CHAD DSCAML1 MLL HMGA2 FHIT KIAA1267 ARL17P1
ACSL3 ETV1 DTX2 PMS2L5 HMGA2 LHFP KIAA1549 BRAF
ACTB GLI1 DUSP10 PRDM16 HMGA2 LPP KIAA1618 ALK
ADHFE1 C8orf46 EBF1 LOC204010 HMGA2 NFIB KIF5B PDGFRA
AFF1 DSCAML1 EFTUD2 KIF18B HMGA2 RAD51L1 KLK2 ETV4
AFF1 ELF2 EIF3K CYP39A1 HMGA2 WIF1 LCP1 BCL6
AFF1 FXYD6 EIF4A2 BCL6 HMGXB3 PPARGC1B LDHC SERGEF
AFF1 PBX1 ELAC1 SMAD4 HN1 USH1G LEO1 SLC12A1
AFF1 RABGAP1L ELF2 MLL HNRPA2B1 ETV1 LIFR PLAG1
AFF3 BCL2 ELF4 ERG HOOK3 RET LMAN2 AP3S1
AGPAT5 MCPH1 EML1 ABL1 HPS4 ASPHD2 LOC100129406 CTTNBP2NL
AHCYL1 RAD51C EML4 ALK HSP90AA1 BCL6 LOC100131434 FLJ44451
AKAP9 BRAF EPC1 PHF1 HSPH1 PREI3 LPP BCL6
AMD1 GAPDH ERC1 PDGFRB IFNGR2 RUNX1 LPP C12ORF9
ANKHD1 C5orf32 ERO1L FERMT2 IGH@ BCL10 LRMP BCL6
ANKRD28 NUP98 EST14 ETV1 IGH@ BCL11A LRRC57 SNAP23
ARFGEF2 SULF2 ETV6 ABL1 IGH@ BCL2 MACROD1 RUNX1
ARHGAP19 DRG1 ETV6 ABL2 IGH@ BCL3 MALAT1 TFEB
ASPSCR1 TFE3 ETV6 ACSL6 IGH@ BCL6 MALT1 MAP4
ASTN2 PTPRG ETV6 ARNT IGH@ BCL8 MBNL1 BCL6
ASTN2 TBC1D16 ETV6 BAZ2A IGH@ BCL9 MBOAT2 PRKCE
ATIC ALK ETV6 CDX2 IGH@ CCND1 MBTPS2 YY2
AX747630 ETV1 ETV6 EVI1 IGH@ CCND2 MDS1 EVI1
BC017255 TMEM49 ETV6 FGFR3 IGH@ CCND3 MED8 ELOVL1
BCAS4 BCAS3 ETV6 FLT3 IGH@ CCNE1 MEF2D DAZAP1
BCAS4 PRKCBP1 ETV6 FRK IGH@ CD44 MIA RAB4B
Gene Fusion Gene Fusion Gene Fusion Gene Fusion
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5' Gene 3' Gene 5' Gene 3' Gene 5' Gene 3' Gene 5' Gene 3' Gene
BCL11B NKX2 ETV6 GOT1 IGH@ CDK6 MIPOL1 DGKB
BCL11B TLX3 ETV6 ITPR2 IGH@ CEBPA MKL1 RBM15
BCL11B TRD@ ETV6 JAK2 IGH@ CEBPB MLL SEPT2
BCL3 MYC ETV6 MDS1 IGH@ CEBPD MLL SEPT5
BCL6 CIITA ETV6 MDS2 IGH@ CEBPE MLL SEPT6
BCL6 IKZF1 ETV6 NCOA2 IGH@ CEBPG MLL SEPT9
BCL6 IL21R ETV6 NTRK3 IGH@ CHST11 MLL SEPT11
BCL6 PIM1 ETV6 PDGFRA IGH@ CNN3 MLL ABI1
BCR ABL1 ETV6 PDGFRB IGH@ CRLF2 MLL ACACA
BCR FGFR1 ETV6 PER1 IGH@ DDX6 MLL ACTN4
BCR JAK2 ETV6 PTPRR IGH@ EPOR MLL AFF1
BCR PDGFRA ETV6 RUNX1 IGH@ ERVWE1 MLL AFF3
BGLAP PMF1 ETV6 STL IGH@ ETV6 MLL AFF4
BIRC3 MALT1 ETV6 SYK IGH@ FCGR2B MLL ARHGAP26
BOLA2 SMG1 EWSR1 ATF1 IGH@ FCRL4 MLL ARHGEF12
BRCC3 FUNDC2 EWSR1 CREB1 IGH@ FGFR3 MLL ARHGEF17
BRD3 C15orf55 EWSR1 DDIT3 IGH@ FOXP1 MLL BCL9L
BRD4 C15orf55 EWSR1 ERG IGH@ ID4 MLL C2CD3
BRD4 C15ORF55 EWSR1 ETV1 IGH@ IGL@ MLL CASC5
BTG1 MYC EWSR1 ETV4 IGH@ IL3 MLL CASP8AP2
C15ORF21 ETV1 EWSR1 FEV IGH@ IRF4 MLL CBL
C19ORF25 APC2 EWSR1 FLI1 IGH@ KDM4C MLL CIP29
C1orf151 NBL1 EWSR1 NFATC2 IGH@ LHX4 MLL CREBBP
C1QTNF6 IL2RB EWSR1 NR4A3 IGH@ MAF MLL DAB2IP
C20orf29 VISA EWSR1 PATZ1 IGH@ MAFB MLL DCP1A
C22orf39 HIRA EWSR1 PBX1 IGH@ MALT1 MLL DCPS
C3ORF27 EVI1 EWSR1 POU5F1 IGH@ MUC1 MLL EEFSEC
CACNA2D4 WDR43 EWSR1 SP3 IGH@ MYC MLL ELL
CANT1 ETV4 EWSR1 WT1 IGH@ MYCN MLL EP300
CAPRIN1 PDGFRB EWSR1 ZNF384 IGH@ NFKB2 MLL EPS15
CARS ALK EWSR1 ZNF444 IGH@ ODZ2 MLL FLNA
CBFB MYH11 FBXL18 RNF216 IGH@ PAFAH1B2 MLL FNBP1
CCDC6 PDGFRB FCHSD1 BRAF IGH@ PAX5 MLL FOXO3
CCDC88C PDGFRB FGFR1 PLAG1 IGH@ PCSK7 MLL FOXO4
Gene Fusion Gene Fusion Gene Fusion Gene Fusion
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5' Gene 3' Gene 5' Gene 3' Gene 5' Gene 3' Gene 5' Gene 3' Gene
CCDC94 MLL FGFR1 ZNF703 IGH@ RHOH MLL FRYL
CCND1 FSTL3 FGFR1OP FGFR1 IGH@ SPIB MLL GAS7
CCND1 TACSTD2 FGFR1OP2 FGFR1 IGH@ TRA@ MLL GMPS
CCT3 C1orf61 FIP1L1 PDGFRA IGH@ TRD@ MLL GPHN
CD74 ROS1 FIP1L1 RARA IGH@ WHSC1 MLL KIAA0284
CDH11 USP6 FLJ35294 ETV1 IGK@ BCL10 MLL LAMC3
CDK5RAP2 PDGFRA FOXP1 ETV1 IGK@ BCL2 MLL LASP1
CDK6 MLL FPGT TNNI3K IGK@ BCL3 MLL LOC100128568
CENPK MLL FUS ATF1 IGK@ BCL6 MLL LPP
CEP110 FGFR1 FUS CREB3L1 IGK@ CCND1 MLL MAML2
CHCHD7 PLAG1 FUS CREB3L2 IGK@ CCND2 MLL MAPRE1
CHIC2 ETV6 FUS DDIT3 IGK@ CDK6 MLL MLLT1
CHURC1 FNTB FUS ERG IGK@ KDSR MLL MLLT10
CIC DUX4 FUS FEV IGK@ MYC MLL MLLT11
CIITA BCL6 FXYD6 MLL IGK@ PVT1 MLL MLLT3
CLPTM1L PVT1 GAPDH BCL6 IGK@ ZC3H12D MLL MLLT4
CLTC ALK GAS5 BCL6 IGL@ BCL2 MLL MLLT6
CLTC TFE3 GCN1L1 PLA2G1B IGL@ BCL3 MLL MYO1F
CLTCL1 ALK GFOD1 C6orf114 IGL@ BCL6 MLL NCKIPSD
CNBP USP6 GIT2 PDGFRB IGL@ BCL9 MLL NEBL
CNPY2 CS GNA12 SHANK2 IGL@ CCND1 MLL NRIP3
COL1A1 PDGFB GOPC ROS1 IGL@ CCND2 MLL PICALM
COL1A1 USP6 GRB7 PERLD1 IGL@ CCND3 MLL SH3GL1
COL1A2 PLAG1 GRHPR BCL6 IGL@ CDK6 MLL SMAP1
COL6A3 CSF1 HAS2 PLAG1 IGL@ MAF MLL SORBS2
COMMD3 BMI1 HCMOGT1 PDGFRB IGL@ MYC MLL TET1
COX19 ADAP1 HDAC11 FBLN2 IGL@ PVT1 MLL TIRAP
CPSF6 FGFR1 HERPUD1 ERG IGL@ REL MLL TNRC18
CRTC1 MAML2 HERVK FGFR1 IKZF1 BCL6 MLL UBE4A
CRTC3 MAML2 HERVK17 ETV1 IL2 TNFRSF17 MLL VAV1
CTAGE5 SIP1 HERVK22Q11 ETV1 IL6R ATP8B2 MLL ZFYVE19
CTNNB1 PLAG1 HIP1 PDGFRB INPP4A HJURP MLLT10 CLP1
CYTH1 PRPSAP1 HISPPD2A CATSPER2 INTS4 GAB2 MN1 ETV6
DDIT3 MARS HIST1H4I BCL6 IPO11 SLRN MNX1 ETV6
DDX5 ETV4 HJURP EIF4E2 ITK SYK MPO ZNF296
Gene Fusion Gene Fusion Gene Fusion Gene Fusion
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Gene Fusion Gene Fusion Gene Fusion 
5' Gene 3' Gene 5' Gene 3' Gene 5' Gene 3' Gene 
MRPS10 HPR POU2AF1 BCL6 SSH2 SUZ12 
MSI2 HOXA9 PPP2R2A CHEK2 STAT5B RARA 
MSN ALK PRCC TFE3 STIL TAL1 
MYB MNX1 PRKAR1A RARA STRADB NOP58 
MYB NFIB PRKG2 PDGFRB STRN PDGFRA 
MYC BCL7A PRR13 PCBP2 STRN4 TECR 
MYC ZBTB5 PVT1 CHD7 SULF2 PRICKLE2 
MYC ZCCHC7 R3HDM2 NFE2 SUSD1 ROD1 
MYH9 ALK RABEP1 PDGFRB TAF15 NR4A3 
MYO18A FGFR1 RABGAP1L MLL TAF15 ZNF384 
MYO18A PDGFRB RAD51C ATXN7 TAX1BP1 AHCY 
MYO9B FCHO1 RAD54B LOC100128414 TBL1XR1 RGS17 
MYST3 CREBBP RAF1 DAZL TCEA1 PLAG1 
MYST3 EP300 RANBP2 ALK TCF12 NR4A3 
MYST3 NCOA2 RASA2 ACPL2 TCF3 HLF 
MYST3 NCOA3 RB1 ITM2B TCF3 PBX1 
MYST4 CREBBP RBM14 PACS1 TCF3 TFPT 
NAIP OCLN RBM14 RBM4 TCF3 ZNF384 
NAPA BCL6 RBM15 MKL1 TCTA TAL1 
NDE1 PDGFRB RBM6 CSF1R TEX14 PTPRG 
NDUFA13 YJEFN3 RC3H2 RGS3 TFG ALK 
NDUFB8 SEC31B RECK ALX3 TFG NR4A3 
NDUFC2 KCTD14 RERE PIK3CD TFG NTRK1 
NFIA EHF RET CCDC6 TFRC BCL6 
NFKB1 MLL RET ERC1 THAP2 TMEM19 
NIN PDGFRB RET GOLGA5 THRAP3 USP6 
NIT1 DEDD RET KTN1 TIA1 DIRC2 
NME1 NME2 RET NCOA4 TIMM23B LOC100132418 
NONO TFE3 RET PCM1 TMEM199 SARM1 
NOP2 TCF3 RET PRKAR1A TMEM88 TLN1 
NOS1AP C1orf226 RET RFG9 TMPIT STYXL1 
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Gene Fusion Gene Fusion Gene Fusion 
5' Gene 3' Gene 5' Gene 3' Gene 5' Gene 3' Gene 
NPEPPS USP32 RET TRIM24 TMPRSS2 ERG 
NPM1 ALK RET TRIM33 TMPRSS2 ETV1 
NPM1 MLF1 RGS22 SYCP1 TMPRSS2 ETV4 
NPM1 RARA RHOH BCL6 TMPRSS2 ETV5 
NUMA1 RARA RIF1 PKD1L1 TOPORS DDX58 
NUP214 ABL1 RIPK3 ADCY4 TP53BP1 PDGFRB 
NUP214 XKR3 RMND5A ANAPC1 TPM3 ALK 
NUP98 ADD3 RNF103 VPS24 TPM3 NTRK1 
NUP98 CCDC28A Rnf139 Ndufb9 TPM3 PDGFRB 
NUP98 DDX10 RNF216 RBAK TPM3 TPR 
NUP98 HHEX RPL11 TCEB3 TPM4 ALK 
NUP98 HOXA11 RPN1 EVI1 TPR NTRK1 
NUP98 HOXA13 RPN1 PRDM16 TRA@ CDKN2A 
NUP98 HOXA9 RPS10 HPR TRA@ IRF4 
NUP98 HOXC11 RPS6KB1 TMEM49 TRA@ MTCP1 
NUP98 HOXC13 RRM2 C2orf48 TRA@ MYC 
NUP98 HOXD11 RSBN1 BCAS3 TRA@ NOTCH1 
NUP98 HOXD13 RUNX1 AFF3 TRA@ OLIG2 
NUP98 IQCG RUNX1 CBFA2T3 TRA@ PVRL2 
NUP98 KDM5A RUNX1 CPNE8 TRA@ TCL1A 
NUP98 LNP1 RUNX1 EVI1 TRA@ TRB@ 
NUP98 NSD1 RUNX1 FGA7 TRB@ CCND2 
NUP98 PHF23 RUNX1 LPXN TRB@ EVI1 
NUP98 PRRX1 RUNX1 MDS1 TRB@ HOXA@ 
NUP98 PRRX2 RUNX1 PRDM16 TRB@ HOXA10 
NUP98 PSIP1 RUNX1 PRDX4 TRB@ HOXA11 
NUP98 RAP1GDS1 RUNX1 RPL22P1 TRB@ IRS4 
NUP98 SETBP1 RUNX1 RUNX1T1 TRB@ LCK 
NUP98 TOP1 RUNX1 SH3D19 TRB@ LMO1 
NUP98 TOP2B RUNX1 TRPS1 TRB@ LMO2 
NUP98 WHSC1L1 RUNX1 USP42 TRB@ LYL1 
ODZ4 NRG1 RUNX1 YTHDF2 TRB@ MTCP1 
OMD USP6 RUNX1 ZFPM2 TRB@ MYB 
P2RY8 CRLF2 RUNX1 ZNF687 TRB@ NOTCH1 
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Gene Fusion Gene Fusion Gene Fusion 
5' Gene 3' Gene 5' Gene 3' Gene 5' Gene 3' Gene 
PAPOLA AK7 RYK ATP5O TRB@ TAL1 
PARP1 MIXL1 SAMD12 PHF20L1 TRB@ TAL2 
PAX3 FOXO1 SAMD12 PVT1 TRB@ TLX1 
PAX3 FOXO4 SAMD5 SASH1 TRB@ TRG@ 
PAX3 NCOA1 SCAMP2 WDR72 TRD@ LMO1 
PAX3 NCOA2 SDHAF2(C11orf79) C11orf66 TRD@ LMO2 
PAX5 ASXL1 SDHD TEX12 TRD@ NKX2 
PAX5 BRD1 SEC31A ALK TRD@ PVT1 
PAX5 C20ORF112 SET NUP214 TRD@ RANBP17 
PAX5 DACH1 SFPQ ABL1 TRD@ TAL1 
PAX5 ELN SFPQ EIF5A TRD@ TLX1 
PAX5 ETV6 SFPQ TFE3 TRD@ TLX3 
PAX5 FOXP1 SFRS3 BCL6 TRG@ IGH@ 
PAX5 HIPK1 SLC12A7 C11orf67 TRG@ TRB@ 
PAX5 JAK2 SLC20A2 DBX2 TRIM24 FGFR1 
PAX5 KIF3B SLC26A6 PRKAR2A TRIM61 FARSB 
PAX5 LOC392027 SLC34A2 ROS1 TRIP11 PDGFRB 
PAX5 PML SLC45A3 ELK4 TTL ETV6 
PAX5 POM121 SLC45A3 ERG TXLNG SYAP1 
PAX5 SLCO1B3 SLC45A3 ETV1 TYMP SCO2 
PAX5 ZNF521 SLC45A3 ETV5 UBR4 GLB1 
PAX7 FOXO1 SMYD3 ZNF695 USP10 ZDHHC7 
PAX8 PPARG SNHG5 BCL6 USP16 RUNX1 
PBX1 MLL SNRPF CCDC38 WDR51B GALNT4 
PCM1 JAK2 SPOCK1 TBC1D9B WDR55 DND1 
PDCD1LG2 C18orf10 SPTBN1 FLT3 WRB SH3BGR 
PDE4DIP PDGFRB SPTBN1 PDGFRB ZBTB16 RARA 
PICALM MLLT10 SRGAP3 RAF1 ZDHHC7 ABCB9 
PIK3C2A TEAD1 SRP9 RPS8 ZEB2 LOC100128821 
PLA2R1 RBMS1 SS18 SSX ZMIZ1 ABL1 
PLCXD2 PHLDB2 SS18 SSX1 ZMYM2 FGFR1 
PLXND1 TMCC1 SS18 SSX2 ZNF294 TIAM1 
PMF1 BGLAP SS18 SSX4 ZNF649 ZNF577 
PML RARA SS18L1 SSX1 
  POLR2J3 UPK3B SSBP2 JAK2 
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Gene Fusion Class 
TMPRSS2+ERG Dominant 
TAF15+NR4A3 Dominant 
SSX2+SS18 Dominant 
SSX1+SS18 Dominant 
SS18+SSX2 Dominant 
SS18+SSX1 Dominant 
NPM1+ALK Dominant 
KIAA1549+BRAF Dominant 
JAZF1+SUZ12 Dominant 
FUS+DDIT3 Dominant 
EWSR1+WT1 Dominant 
EWSR1+NR4A3 Dominant 
EWSR1+FLI1 Dominant 
EWSR1+ERG Dominant 
EWSR1+CREB1 Dominant 
EWSR1+ATF1 Dominant 
ETV6+NTRK3 Dominant 
ATIC+ALK Dominant 
COL1A1+PDGFB Multiple dominant  
ASPSCR1+TFE3 Multiple dominant  
TMPRSS2+ETV1 No dominant 
TFG+ALK No dominant 
SRGAP3+RAF1 No dominant 
SEC31A+ALK No dominant 
RANBP2+ALK No dominant 
RAF1+ESRP1 No dominant 
PRCC+TFE3 No dominant 
MYB+NFIB No dominant 
MSN+ALK No dominant 
FUS+ERG No dominant 
FUS+CREB3L2 No dominant 
FUS+CREB3L1 No dominant 
EWSR1+ZNF384 No dominant 
EWSR1+SP3 No dominant 
EWSR1+POU5F1 No dominant 
EWSR1+PBX1 No dominant 
EWSR1+PATZ1 No dominant 
EWSR1+ETV4 No dominant 
EWSR1+DDIT3 No dominant 
EML4+ALK No dominant 
CREB3L2+FUS No dominant 
CLTC+ALK No dominant 
 
Table C.2 The list of gene fusions with iso-forms
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Table D.1 The sequences of frame-shifted peptides derived from Indels 
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Table E.1 The list of reaming 76 putative tumor-associated splicing variants 
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Table E.2 The sequences of frame-shifted peptides from splicing variants 
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F.1 EST sequence database 
EST sequences are downloaded from ftp://ftp.ncbi.nlm.nih.gov/blast/db/FASTA. 
The information about the libraries in EST Db were obtained from the file called 
Hs_LibData.dat. This file was downloaded from CGAP under National Cancer 
Institute (NCI); cgap.nci.nih.gov/Info/CGAPDownload. There were 8,627 
libraries from normal and cancer samples in this file (Table F.1). 
Table F.1 The number of libraries in EST database by their origin of sample. 
 
 
 
 
Table F.2 Tumor EST libraries 41 tissue types were presented in tumor 
libraries. 
Tissue type 
No. of 
libraries  Tissue type No. of libraries 
 bone marrow 5   cerebellum* 5 
 placenta 5   liver 27 
 peripheral nervous 
system 1  skin 13 
 cervix 10   adrenal medulla 1 
 head and neck 641   soft tissue 4 
 stomach 248   brain 275 
 prostate 157   bone 9 
 pancreas 18   kidney 136 
 esophagus 4   ovary 158 
 colon 783   adrenal cortex 1 
 nervous 11   germ cell 6 
 endocrine 3   pancreatic islet* 1 
 pituitary gland 1   adipose 1 
 eye 3   mammary gland 731 
 thymus 4   lymphoreticular 18 
 lung 191   synovium 1 
Type No. of EST library 
Normal 2284 
Neoplasia 4410 
Preneoplasia 10 
Uncharacterized 1923 
  142 
 lymph node 8   genitourinary 81 
 salivary gland 2   cartilage 13 
 testis 16   uterus 112 
 gastrointestinal tract 2   muscle 6 
 thyroid 5    
 
Table F.3 Normal EST libraries 48 tissue types were presented in normal 
libraries. 
Tissue type No. of libraries  Tissue type No. of libraries 
 ear 2   thyroid 6 
 bone marrow 11   cerebellum 4 
 placenta* 353   liver 24 
 peripheral nervous 
system 5   vascular 16 
 cervix 1   pineal gland 3 
 head and neck 45   skin 11 
 uncharacterized tissue 102   soft tissue 4 
 stomach 75   brain 66 
 prostate 143   bone 4 
 pancreas 10   kidney 14 
 esophagus 1   spleen 6 
 colon 138   ovary 9 
 nervous 5   pancreatic islet 9 
 endocrine 8   adipose 6 
 pituitary gland 5   whole body 15 
 eye 25   mammary gland 337 
 thymus 7   lymphoreticular 17 
 lung 103   synovium 2 
 lymph node 10   retina 17 
 pooled tissue 99   genitourinary 13 
 salivary gland 4   cartilage 4 
 testis 156   uterus 6 
 heart 15   muscle 9 
 gastrointestinal tract 4   cerebrum 355 
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F.2 RNA-seq data 
Table F.4 The table of RNA-Seq data 
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 I examined all possible frame-shifted (FS) peptides from coding 
sequences. Basically, all coding sequences were translated from second and third 
nucleotide. The translated sequences were splited into each piece by stop codons 
in the middle. The second reading frame of all mRNA generated 803,872 peptides 
while the third reading frame yielded 1,049,355 peptides. Figure G.1 shows the 
distribution of their lengths. Frame-shifted mutations are prone to have more than 
one premature stop codon at the end according to this distrituion. However, short 
frame-shifted peptides wer not made by the excessive number of stop codons. The 
number of stop codins in the second and third reading frames (see Figure G.2) 
were not more or less than expected number by the frequency in the codon table 
(3 stop codons out of all 64 codons). Therefore, the relative positions of stop 
codons actually generated the shorter frame-shifted peptides. 
 
 
Figure G.1 The length of frame-shifted peptides from coding sequences. 
Interestingly, the distribution of length of peptides was totally skewed to 0 or 1 
amino acid long. About 50% of frame-shifted peptides were 10 amino acids long 
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or less. X-axis indicated the length of frame-shifted peptide while y-axis indicated 
the number of peptides of that length.  
 
Figure G.2 The number of stop codons. This figure shows the number of stop 
codons from sequence of which lengths ranged from 100 amino acids to 1,000 
amino acids. Most of translated peptides from second and third frame of coding 
sequences have an expected number of stop codons. 
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